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Hypertension is a worldwide epidemic responsible for 12.8% of all deaths. 
Approximately 10% of hypertensive patients do not respond to current 
treatments and diagnoses are becoming more frequent, necessitating a deeper 
understanding of the disease as well as the development of novel 
antihypertensive therapies. More than half the cases of hypertension are believed 
to be of neurogenic origin, meaning that sympathetic outflow is elevated.  In this 
context, I investigated the feasibility of the central nervous system as a novel 
pharmacological target for the treatment of hypertension.  Glutamate is the major 
excitatory neurotransmitter in the brain and I sought to test the effects of 
compounds that modulate metabotropic glutamate receptor 5 on blood pressure 
and to determine whether their antagonism could reduce blood pressure in a 
well-established rodent model of hypertension.  In addition, I investigated the 
involvement of the adaptive immune system in the pathology of human 
hypertension, since sympathetic outflow is known to drive inflammation and 
inflammation itself is pro-hypertensive. Using immunohistochemistry in 
autonomic regions of the brain, I found no obvious difference in the expression 
of metabotropic glutamate receptor 5 between normotensive and neurogenically 
hypertensive rat strains. However, using radio-telemetry, I observed a short-term 
increase in blood pressure of normotensive wild-type rats, produced by 
potentiation of the response of metabotropic glutamate receptor 5 to endogenous 
glutamate and a short-term decrease in the blood pressure of hypertensive rats 
with an antagonist of the same receptor.  I also demonstrated a difference 
between the immunophenotypes of hypertensive and normotensive human males, 
consistent with increased activity of the adaptive immune system in 
hypertension. Further studies are needed to explore the potential of mGluR5 




receptors as a central nervous system target for lowering arterial pressure in 
neurogenic hypertension. My data fully support a specific inflammatory process 
associated with hypertension and future studies will need to disentangle the 
cause-effect relationship between autonomic and adaptive inflammatory 
mechanisms. Nevertheless, combination therapy targeting specific metabotropic 
glutamatergic receptors and inflammatory mechanisms may offer a novel 
approach for ameliorating high blood pressure. 
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Chapter 1:  General Introduction 
Hypertension: 
Hypertension is a worldwide epidemic.  It is estimated to cause 12.8% of all 
deaths globally (World Health Organistation, 2017).  The condition affects 1 in 3 
people in the United States (Merai et al., 2016) and the UK (Health Survey for 
England, 2015).  It is the primary risk factor for stroke and is a risk factor for 
heart attack, heart failure and kidney disease as well as other debilitating and 
deadly conditions such as vascular dementia (Forette et al., 1998).  It is usually 
asymptomatic, which can result in at-risk hypertensives failing to seek treatment 
until a severe consequence has been realised. 
95% of hypertensives are diagnosed with “primary” (or “essential”) 
hypertension, meaning that the condition is not secondary to a known pre-
existing condition (Carretero & Oparil, 2000).  Despite a great deal of research, a 
clear understanding of the aetiology of hypertension has not yet been attained.   
Several behavioural factors and lifestyle choices are believed to be contributing 
factors, such as high salt intake, lack of physical activity, obesity and stress 
(Carretero and Oparil, 2000). Genetic factors are also believed to play a role. 
Most research has focussed on the culpability of the renal system and because of 
this, most therapeutic interventions target components of it, such as the enzymes 
of the renin-angiotensin system (RAS), for example angiotensin-converting 
enzyme inhibitors (ACE inhibitors) and diuretics, used to simply reduce blood 
volume and thereby blood pressure.  These treatments are effective in some 
patients, but some remain hypertensive despite receiving a number of 
pharmacological interventions.  A patient that remains hypertensive despite 
receiving three antihypertensive drugs of different classes (one of which must be 




a diuretic) is classified as having resistant hypertension.  These patients account 
for approximately 10% of hypertensives (Persell, 2011).   
The fact that we are unable to control the blood pressure of many hypertensive 
patients along with the fact that the number of sufferers is expected to increase 
means that the global burden of hypertension is bound to worsen.  This 
necessitates the development of novel therapeutic interventions. 
Over 50% of cases of hypertension are estimated to be neurogenic (Esler et al., 
2010) which refers to hypertension in which sympathetic outflow and 
consequently angiotensin II (ANG II) are elevated.  Like drugs targeting the 
RAS, other drugs targeting the downstream mediators of sympathetic activity 
such as β adrenergic receptor blockers (β blockers) have had some success in 
treating the condition.  It was my intention to target the sympathetic nervous 
system upstream of this, in the CNS itself, in an attempt to investigate the 
feasibility of the CNS as a novel pharmacological target for the treatment of 
hypertension. 
Basics of Blood Pressure Control: 
Blood pressure (BP) is controlled by the autonomic nervous system.  This 
complex neuronal network integrates afferent information from chemical and 
mechanical sensors in the periphery and adjusts the efferent sympathetic and 
parasympathetic tone that flows out to organs with the capability to effect 
changes in BP such as the heart, blood vessels and kidneys.  An increase in 
sympathetic activity results in contraction of vascular smooth muscle, causing 
vasoconstriction, which results in an increase in total peripheral resistance (TPR) 
which reduces blood flow and increases arterial pressure.   Sympathetic 
activation causes heart rate and contractility to increase.  It also causes the 




kidneys to retain more salt and release renin, which elevates circulating 
angiotensin II, and aldosterone which results in increased blood volume.  These 
effects synergise to produce an increase in the cardiac output (CO).  Thus, mean 
arterial pressure (MAP) can be defined as follows: 
MAP = CO x TPR 
Blood pressure is normally around 120/80mmHg where 120 mmHg is the 
systolic pressure and 80 mmHg is the diastolic pressure (Blood Pressure UK, 
2017).  Systolic pressure is the pressure exerted on the blood vessels during the 
heart beat and the diastolic reading is the pressure when the heart is resting 
between beats. Hypertension (high blood pressure) is defined as BP that is 
measured consistently at or above 140/90mmHg (Blood Pressure UK, 2017).  
Figure 1 is a chart displaying how different blood pressure readings are 
medically categorised for adults: 
 
Figure 1:  Blood pressure categories as defined by Blood Pressure UK 
 Blood pressure fluctuates throughout the day and has a diurnal rhythm. It also 
has a minute-to minute variability reflecting body posture, mental state and the 
level of physical activity, for example.  Despite these fluctuations, the average 




BP over the course of a day is tightly controlled.  The mechanism by which the 
set point (120/80 mmHg) is established and how this may change in the case of 
hypertension is not fully understood.  However, a great deal of information 
concerning the operation of blood pressure control neural circuitry has been 
obtained and will be discussed later on.   
The Autonomic Nervous System and Angiotensin II: 
As alluded to earlier, blood pressure is controlled by the autonomic nervous 
system. The efferent fibres of the autonomic nervous system constitute the 
sympathetic and parasympathetic systems; parallel neuronal networks.  The 
sympathetic pre-ganglionic neurones located in the intermediolateral cell column 
of the spinal cord project to and innervate the post-ganglionic sympathetic motor 
neurons in the paravertebral chain. The latter cells project to and control vascular 
smooth muscle and visceral organs such as the kidney.  These post-ganglionic 
motor neurones are mostly noradrenergic, whereas the preganglionic neurons are 
cholinergic. The visceral afferents providing sensory information to the CNS are 
primarily glutamatergic.  
Stimulation of post-ganglionic sympathetic motor neurones causes contraction of 
vascular smooth muscle (increased vasomotor tone), increased heart rate / 
contractility and increased renin release in the kidneys.  Renin is a component of 
the renin-angiotensin system (RAS), which acts to increase blood pressure by 
raising peripheral vascular resistance and increasing blood volume.  Renin is an 
enzyme which converts circulating angiotensionogen into angiotensin I (ANG I).  
ANG I is then converted into angiotensin II (ANG II), mostly in the lungs by 
angiotensin converting enzyme (ACE).  ANG II is pharmacologically active and 
acts via receptors on vascular smooth muscle cells to cause vasoconstriction.  It 




also stimulates thirst and causes the release of vasopressin from the pituitary 
gland, which is an endogenous antidiuretic.   
The circumventricular organs (CVOs) are structures in the CNS that are 
incompletely protected by the blood brain barrier (BBB)- a selectively-
permeable membrane that separates circulating blood from the cerebrospinal 
fluid in order to protect the brain parenchyma from chemicals that would 
otherwise damage it.  This incomplete barrier of CVOs allows certain 
pharmacologically active agents in the circulating blood to act on targets in the 
CNS and ANG II is one such agent.  It acts at the subfornical organ (SFO), 
another CVO which contains AT1 receptors.  Activation of these receptors 
stimulates neurones in the SFO which project to and excite neurones in the 
paraventricular nucleus of the hypothalamus (PVN), which itself projects to the 
medulla oblongata of the brainstem (simply termed the medulla from here on), a 
region containing the most essential nuclei concerned with blood pressure 
control, which will be discussed later, and the spinal cord. These PVN 
projections are sympathoexcitatory in function and when activated, raise arterial 
blood pressure.  
Sympathetic preganglionic neurones also innervate the adrenal glands, from 
which adrenaline, noradrenaline (NA) and aldosterone are released.  All of these 
hormones raise blood pressure; adrenaline and NA act via α and β 
adrenoreceptors to increase peripheral vascular resistance (via contraction of 
vascular smooth muscle) and increasing heart rate/contractility, respectively.  
Aldosterone, like vasopressin, causes the renal system to retain more sodium, 
resulting in water retention.  This increases blood volume and thereby blood 
pressure.   




The parasympathetic efferents concerned with blood pressure control project 
from the CNS to ganglia within or adjacent to their target organs; the heart and 
some blood vessels.  Their activity has opposite effects to the sympathetic 
nervous system, reducing heart rate and contractility and thereby blood pressure.  
Most blood vessels do not have parasympathetic innervation although some do, 
such as those in the genital erectile tissue as well as gastrointestinal and salivary 
glands.  Parasympathetic activity causes vasodilation in these vessels, facilitating 
specialist functions where increased blood flow is required locally. (Purves et al., 
2001; Sato & Ishii, 2017) 
Since neurogenic hypertension is characterised by over-activity of the 
sympathetic nervous system, sympathetic outflow will be the focus of this thesis.   










Situated in the brainstem, the rostral ventrolateral medulla (RVLM) contains 
important sympathetic vasomotor premotor neurons that are responsible for the 
Figure 2:  Schematic outlining key nuclei involved in blood pressure control.  SFO: Subfornical organ; PVN: 
Paraventricular nucleus of the hypothalamus; PAG: Periaqueductal grey area; A5: A5 area of the ventrolateral pons; 
NTS: Nucleus tractus solitarii; RVLM: Rostral ventrolateral medulla; CVLM: Caudal ventrolateral medulla. Plus 
signs indicate excitatory inputs, minus signs indicate inhibitory inputs. 




tonic excitatory drive that maintains vasomotor tone as well as heart rate and 
cardiac contractility (Dampney, 1994; Blessing, 1997; Guyenet, 2006). These 
neurons, along with others that innervate the kidneys and are able to control 
sodium retention and renin release, project to the intermediolateral nucleus 
(IML) in the spinal cord from where they stimulate the preganglionic 
sympathetic neurons (Ross et al., 1984; Brown & Guyenet, 1985; Morrison et 
al., 1988; Milner et al., 1988; Lipski et al., 1995; Schreihofer & Guyenet, 1997). 
Stimulation of the RVLM greatly increases sympathetic nerve activity (SNA) 
and BP (Willette et al., 1983; Ross et al., 1984; Guyenet & Brown, 1986; 
Morrison et al., 1988; Schreihofer et al., 2000).   Inhibition of the region has the 
opposite effect (Schreihofer et al., 2000).  More recently, Bukre et al., used an 
optogenetic approach to selectively stimulate the C1 catecholaminergic neurones 
of the RVLM and observed cardiorespiratory hypertension (Burke et al., 2014).  
Abbott et al. used a different optogenetic approach and observed “sizeable 
sympathoactivation and a rise in blood pressure in response to selective 
stimulation of the C1 neurones of the RVLM” (Abbott et al., 2009). The essential 
role played by the RVLM in BP control is extremely well established (Figure 2). 
The C1 neurones are a group of adrenergic neurons situated in the RVLM.  
Many of the caudal C1 neurones project to higher centres such as the 
hypothalamus.  The rostral C1 neurones are considered sympathetic premotor 
neurones since they project to the spinal cord and carry efferent sympathetic 
activity.  
The caudal ventrolateral medulla (CVLM) moderates the sympathetic outflow 
from the RVLM via tonic GABAergic inhibition.  Injecting bicuculline into the 
RVLM in order to inhibit GABAA receptors markedly increases SNA and BP 




(Willette et al., 1984; Kubo & Kihara, 1987; Masuda et al., 1992; Natarajan & 
Morrison, 1999) and preventing GABA synthesis via injection of 3-
mercaptopropionic acid produces the same effect (Kubo & Kihara, 1987).  The 
CVLM is known to contain GABA-containing neurones that project to the 
RVLM (Minson et al., 1997; Chan & Sawchenko, 1998).  Excitation of neurons 
in the CVLM via injection of glutamate reduces SNA and BP (Willette et al., 
1983; Minson et al., 1997). Inhibiting these cells produces the reverse effect 
(Willette et al., 1983; Natarajan & Morrison, 1999).  Conclusively, inhibition of 
GABA receptors in the RVLM abolishes the effects observed with stimulation or 
inhibition of upstream neurons in the CVLM (Willette et al., 1984; Blessing, 
1988). Goodchild and Moon reviewed evidence demonstrating the involvement 
of the CVLM in cardiovascular regulation in 2009 (Goodchild & Moon, 2009). 
The CVLM receives projections from the Nucleus of the Solitary tract (NTS), 
located in the dorsal medulla (Aicher et al., 1995).  The NTS is a critical 
component of the autonomic nervous system and is involved in the operation of 
both sympathetic and parasympathetic regulation of blood pressure.  Lesioning 
of the NTS causes fatal hypertension (Doba & Reis, 1973). This hypertension 
was characterised by extreme vasoconstriction and was not prevented by prior 
removal of adrenal glands and kidneys, nor was it due to changes in blood gas 
concentrations, as these were measured (Doba & Reis, 1973). It was however, 
blocked by phentolamine, an α-adrenergic receptor antagonist, which suggests 
that the hypertension was neurogenic (Doba & Reis, 1973).   The effect of NTS 
lesioning was prevented by mid-collicular decerebration, implicating more 
rostral structures in the hypertensive response, such as the paraventricular 
nucleus of the hypothalamus (discussed later).  The normal reflex bradycardia 
evoked by intravenous infusion of norepinephrine or angiotensin II was 




abolished by NTS lesioning (Doba & Reis, 1973) and sometimes tachycardia 
was observed.  This means that not only was tonic control of baseline BP lost as 
a result of the lesions, but reflex control in response to acute challenge was lost 
as well. 
The NTS is the site of visceral afferent termination (Andresen & Kunze, 1994) 
and serves as the point of integration of afferent signals from mechanosensitive 
baroreceptors located in the carotid sinus and the aortic arch, as well as 
chemoreceptors, which detect the concentration of oxygen and carbon dioxide 
along with pH.  These are also located at the bifurcation of the common carotid 
artery and in the aortic arch but exist as ‘bodies’, separate to the baroreceptors 
(Pijacka et al., 2018). 
The findings from Doba and Reis’ paper can partially be explained by the loss of 
the baroreflex.  The baroreflex is an essential negative feedback mechanism for 
the control of blood pressure.  The mechanosensitive baroreceptors are 
specialised afferents innervating the arterial wall (Blessing, 1997).  These 
afferents project to the NTS and fire action potentials continuously (tonic 
activity). When the arterial wall is distended due to systole, the rate at which 
these action potentials are fired increases proportional to the magnitude of the 
distension. With every beat of the heart, impulses are relayed to the NTS.  In the 
case of the carotid sinus baroreceptors, the signal is sent via the carotid sinus 
nerve, which is a branch of the glossopharyngeal nerve (IXth cranial nerve).   The 
aortic baroreceptor afferents project to the NTS via the aortic nerve, a branch of 
the vagus nerve (Xth cranial nerve).  Afferents from the carotid and aortic bodies 
(chemoreceptors) arrive at the NTS together with the baroreceptor afferents via 
glossopharyngeal and vagal projections, respectively. 




There are 2 subdivisions of baroreceptor afferents.  Type 1 afferents have 
myelinated axons, giving them fast conduction velocities.  They have pulse 
modulated discharge patterns and are believed to be involved in the response to 
sudden changes in BP (Seagard et al., 1990). Blocking these fibres attenuates the 
baroreflex but overall MAP remains unchanged (Dean & Seagard, 1997). 
Type 2 baroreceptor afferents are smaller and have little or no myelination.  As a 
result, they have slow transmission velocities and they discharge with minimal 
pulse modulation but increase firing as arterial pressure is raised.  These 
afferents are believed to be involved in long-term baseline control of BP around 
a set point but this remains controversial (Seagard et al., 1990). 
When baroreceptors are activated, action potentials are sent to the NTS via the 
glossopharyngeal and vagal nerves that excite neurons in the NTS which project 
to and excite (via glutamate) neurons in the CVLM.  This results in release of 
GABA and the resulting inhibition of presympathetic neurons in the RVLM as 
discussed earlier.  There may be an additional sympathoinhibitory pathway from 
the NTS directly to the IML (Coote & Macleod, 1974; Lewis & Coote, 1995).  
Baroreceptor inputs to the NTS also activate neurons that project to the nucleus 
ambiguus and dorsal motor nucleus of the vagus (McAllen & Spyer, 1978; 
Standish et al., 1995; Jones et al., 1998; Jones, 2001; Llewellyn-Smith & 
Anthony Verberne, 2011).  These nuclei send pre-ganglionic parasympathetic 
efferents to the heart, reducing heart rate via post-ganglionic neurones located 
within ganglia on the heart itself (Dampney, 1994).   
Neurons projecting from the NTS to the CVLM and operating as part of the 
baroreflex arc are not the only source of excitatory drive stimulating the CVLM 
to engage in GABAergic inhibition of the RVLM.  Iontophoretic application of 




bicuculline to the RVLM causes activation of presympathetic neurons even 
under conditions in which BP has been lowered to below the threshold for 
baroreflex activation (Sun & Guyenet, 1985).  Further, at low BP, neurons in the 
RVLM still receive inhibitory post-synaptic potentials despite the lack of 
baroreflex activation.  Microinjection of bicuculline into the RVLM of animals 
that have had their baroreflex abolished via sinoaortic denervation sill results in 
an increase in SNA and BP (Kubo & Kihara, 1987; Dampney et al., 1988). From 
these studies we can conclude that the RVLM receives chronic GABAergic 
inhibition that is independent of the baroreflex.  The fact that inhibition of the 
CVLM exacerbates the increased SNA and BP caused by sinoaortic denervation 
or lesioning of the NTS provides evidence that the source of this baroreflex-
independent inhibition of the RVLM is the CVLM (Cravo & Morrison, 1993). 
Structures in the midbrain are involved in blood pressure control.  The neurons 
of the A5 area of the ventrolateral pons (A5 area) have spinal projections 
targeting mostly the intermediolateral cell column (Loewy et al., 1979b; Byrum 
& Guyenet, 1987).  These neurons are thought to regulate sympathetic outflow, 
especially in relation to respiration (Koshiya & Guyenet, 1994; Hilaire et al., 
2004; Zanella et al., 2006). 
The A5 area connects to the NTS, CVLM, RVLM, caudal pressor area and the 
retrotrapezoid nucleus (which detects CO2 and pH in order to regulate breathing) 
in the medulla oblongata, with the medial, Kölliker–Fuse and lateral parabrachial 
nuclei (which regulate normal respiratory rate) in the pons, and, the PVN and the 
amygdala in the hypothalamus (Byrum & Guyenet, 1987; Tavares et al., 1997; 
Sun & Panneton, 2005; Rosin et al., 2006; Abbott et al., 2012). 




The fact that the A5 area is associated with these other nuclei suggests a possible 
role for it in the control of cardiorespiratory activity (Spyer, 1994; Dampney et 
al., 2003; Taxini et al., 2011).  Guyenet et al. showed that neurons in the A5 area 
are excited in response to peripheral chemoreceptor activation due to hypoxia 
(Guyenet et al., 1993).  Increasing blood pressure causes spontaneous activity of 
A5 neurons to decrease and vice versa (Andrade & Aghajanian, 1982). This 
suggests that A5 neurones are modulated by visceral afferents controlling 
cardiorespiratory function. 
Various groups have attempted to delineate the specific role A5 neurons play in 
autonomic regulation.  Using methods including microinjection of glutamate 
agonists and electrical stimulation, several groups observed slight changes in 
blood pressure (Loewy et al., 1979a; Neil & Loewy, 1982; Stanek et al., 1984; 
Maiorov et al., 1999, 2000). The precise role of the neurons was not clearly 
established, as it is very difficult to stimulate these neurons selectively, given 
their small number and sparse distribution within the dorsolateral pons as well as 
the fact that they are located close to the superior olivary complex, the reticular 
formation and the trigeminal nerve, neurons from each of which were almost 
certainly stimulated along with the A5 neurons. 
An optogenetic approach has been taken in order to stimulate the A5 neurons 
specifically (Kanbar et al., 2011).  This produced a large but short-lasting 
increase in renal sympathetic outflow, followed by a short period of inhibition.  
A similar but considerably smaller effect was observed in the lumbar 
sympathetic outflow.   It is not known whether the A5 area contains mGluR5 but 
if it does it may be the case that modulation of mGluR5 in this region could 




reduce sympathetic outflow from the RVLM and contribute to reducing BP in 
hypertension.  
Another midbrain structure involved in the control of blood pressure is the 
periaqueductal grey (PAG).  The PAG is divided into four regions based upon 
function.  These regions consist of columns that run longitudinally and are 
defined by their location relative to the fourth ventricle (Figure 3):  The 
dorsomedial PAG (dmPAG), dorsolateral PAG (dlPAG), lateral PAG (lPAG) 








The vlPAG contains many neurones that project to key areas involved in the 
control of blood pressure such as the medulla (Carrive et al., 1988) and 
hypothalamic nuclei (ter Horst et al., 1984; Uschakov et al., 2009).  Stimulation 
of the vlPAG reduces BP and HR in anaesthetised animals via inhibition of 
sympathetic premotor neurones in the RVLM (Lovick, 1992; Farkas et al., 1998) 
and there is some evidence that dorsal PAG is overactive in SHR (Schenberg et 






Figure 3:  Schematic of a coronal section of the periaqueductal gray 
area (PAG) of the rat brain showing the various subregions and the 
cardiovascular control regions their neurones project to. dmPAG: 
Dorsomedial PAG; dlPAG: dorsolateral PAG; lPAG: Lateral PAG; vlPAG: 
Ventrolateral PAG; Aq: Cerebral aqueduct; NTS: Nucleus of the solitary 
tract 
Medulla and hypothalamic nuclei 
NTS 




facilitates the arterial baroreflex in anaesthetised wild type rats (Inui et al., 
1994).   
The dorsolateral PAG is known to play a vital role in the “fight or flight” 
response that is initiated in response to a perceived threat such as a predator.  
This response is characterised by several immediate changes to cardiovascular 
and respiratory activity including tachycardia, hyperventilation, increased blood 
pressure, baroreceptor reflex inhibition and an increase in blood flow to the 
skeletal muscles (Carrive, 1993; Hayward, 2007; Netzer et al., 2011).  
Interestingly, due to distinct but parallel circuitry within the PAG, the opposite 
pattern of cardiovascular and respiratory effects is elicited from the ventrolateral 
area and under conditions in which a threat is inescapable (Bandler et al., 2000).  
This generates a “play dead” response and whether it is this response or the 
“fight or flight” response that is elicited by a threat depends upon activity higher 
in the cerebrum.  Chemical ablation of the dlPAG results in an increase in 
baroreflex tachycardia but has no effect on reflex bradycardia (Pelosi et al., 
2007) suggesting the dlPAG tonically inhibits the baroreflex.  The dlPAG is 
known to contain afferents that project to the NTS (Boscan & Paton, 2005). 
Taken together, the above evidence demonstrates a role for the PAG, in 
particular the dlPAG and vlPAG in cardiovascular control.  
Sympathetic Nervous System Activity is Elevated in Hypertension: 
Increased sympathetic nerve activity has been implicated in the pathogenesis of 
hypertension.  The spontaneously hypertensive rat (SHR) is an animal model of 
essential hypertension in which sympathetic nerve activity has been shown to be 
elevated (Judy et al., 1976; Li & Pan, 2007).  The same has been observed in 
hypertensive humans (Anderson et al., 1989; Grassi, 1998; Mancia et al., 1999)  




The paraventricular nucleus of the hypothalamus (PVN) is a key region involved 
in neuroendocrine and cardiovascular homeostasis. (Martin & Haywood, 1992; 
Coote et al., 1998; Dampney et al., 2005).  Lesioning of the PVN in 
spontaneously hypertensive rats (SHRs) reduces blood pressure (Ciriello et al., 
1984; Takeda et al., 1991) and inhibition of the PVN with muscimol, a GABAA 
receptor agonist, reduces BP and SNA in these animals (Akine et al., 2003).  
Interestingly, antagonism of glutamate receptors in the PVN in normotensive rats 
has little effect on blood pressure or sympathetic activity (Chen et al., 2003; 
Zahner & Pan, 2005).  These findings suggest that glutamatergic signalling in the 
PVN does not have a large role to play in the tonic regulation of sympathetic 
vasomotor tone in normotensive animals but may be contributing to the 
pathological increase in SNA observed in hypertension. 
Li and Pan (2007) bilaterally injected AP5, an NMDA antagonist, or CNQX, an 
AMPA/kainite receptor antagonist, into the PVN and with both drugs, observed a 
dose-dependent reduction in lumbar SNA, mABP and HR in SHRs but not in 
Wistar-Kyoto (WKY) normotensive rats.  Separately, they also injected 
gabazine, a GABAA receptor antagonist into the PVN and found that this 
increased lumbar SNA, mABP and HR in both SHRs and normotensive WKY 
rats.  Interestingly, this effect was much larger in the normotensive animals than 
it was in the hypertensives and it was blocked by kynurenic acid, a glutamate 
antagonist.  This work provided further evidence that the elevated sympathetic 
vasomotor tone observed in hypertension is maintained, at least in part, by tonic 
glutamatergic signalling in the PVN.   




Metabotropic Glutamate Receptor 5 (mGluR5): 
Glutamate is the principle excitatory neurotransmitter in the CNS.  It acts via 
both ionotropic receptors, which are ligand gated ion channels which are directly 
involved in very fast responses such as neurotransmission, as well as 
metabotropic receptors that act more slowly through a second messenger 
(Hermans & Challiss, 2001).  mGluR5 is a class C metabotropic G-protein-
coupled receptor (GPCR) for glutamate.  The class C GPCRs have a large 
extracellular N-terminal sequence containing a hydrophilic ligand-binding 
region, seven transmembrane domains and a cytoplasmic C-terminal domain 
with which a G-protein is associated (Bräuner-Osborne et al., 2007) .  The G-
proteins transduce the signal from the ligand via an intracellular signalling 
cascade with various end products and effects depending on the protein.  
mGluRs are divided into 3 groups based on their pharmacology, sequence 
homology and transduction mechanisms (Niswender & Conn, 2010; Yin & 
Niswender, 2014).  mGluR5, of which there are two isoforms: mGluR5a and 
mGluR5b, along with mGluR1 are classed as a group 1 mGluRs.  mGluR5a 
dominates in the early post-natal developmental period while mGluR5b is most 
prevalent in the adult (Minakami et al., 1993; Romano et al., 1996).  These 
receptors are expressed on post-synaptic neuronal membranes and are coupled to 
Gq/11, a heterotrimeric G protein subunit that is composed of Gα, Gβ and Gγ 
(Syrovatkina et al., 2016). When activated via a ligand-induced conformational 
change in the associated metabotropic receptor, phospholipase C is activated 
(Harden et al., 2011).  This enzyme hydrolyses membrane phosphatidylinositol 
4,5-bisphosphate (PIP2), resulting in the formation of inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG) (Essen et al., 1997).  IP3 diffuses 
through the cytosol to IP3 receptors on the endoplasmic reticulum.  These 




receptors are ligand-gated ion channels for Ca2+ and their activation allows 
calcium to flow from the endoplasmic reticulum into the cytosol (Berridge, 
2009).  Ca2+ activates protein kinase C (PKC), an enzyme family that 
phosphorylates hydroxyl groups on amino acid residues of other proteins.  DAG 
activates the same enzyme (Matosin et al., 2012).  Increased intracellular 
calcium and the activity of PKC increase the excitability of the cell, making 
action potentials more likely (Li and Pan, 2014).  An overview of mGluR5 
signalling is shown in Figure 4: 
 
 
Figure 4: Schematic outlining mGluR5 signalling pathway from Yang et al. (2004). mGluR5 = metabotropic 
glutamate receptor 5, DAG = diacylglycerol, IP3 = Inositol trisphosphate, PKC = Protein kinase C. 
 
The cytosolic C-terminal domain of mGluR5 is bound to Homer proteins.  
Homer proteins are scaffolding proteins present primarily at the post-synaptic 
density in neurones throughout the CNS.  They can be divided into two 




categories; the short form (1a) and the long forms (1b, 1c 2 and 3).  The long 
form Homers are expressed constitutively (Xiao et al., 1998; Soloviev et al., 
2000) and multimerize via their c-terminal coiled-coil domains, which in 
combination with interaction with other scaffolding proteins such as SH3 and 
multiple ankyrin repeat domains protein (SHANK3), promotes localisation of 
mGluR5 to the post-synaptic density of the synapse and couples the receptor to 
its downstream mediators, thereby facilitating synaptic transmission (Kato et al., 
1998; Tu et al., 1998; Xiao et al., 1998). The short form 1a variant is expressed 
in response to synaptic activity (Brakeman et al., 1997; Vazdarjanova et al., 
2002).  Homer 1a lacks the coiled-coil domain used by the long forms to 
multimerize and as such is unable to do so.  This means that Homer 1a disrupts 
long form Homer chains and inhibits mGlur5 function (Xiao et al., 2000; 
Kammermeier & Worley, 2007).  Thus, Homer 1a is induced after synaptic 
activity and acts as a homeostatic mechanism to uncouple mGluR5 and reduce 
intracellular Ca2+ release, thereby preventing excessive neuronal activity and 
excitotoxicity.    
Evidence for involvement of mGluR5 in arterial pressure control specifically in 
the PVN was demonstrated by Li and Pan (Li & Pan, 2010), when they 
bilaterally injected specific antagonists for both group 1 mGluRs into the PVN 
and observed dose-dependent decreases in mABP, lumbar SNA and HR in SHRs 
but not in WKY rats.  The effects were greater with antagonism of mGluR5 
compared to mGluR1 suggesting a key role for mGluR5 in particular.  Further, 
injection of the non-specific group 1 mGluR agonist (S)-3,5-
Dihydroxyphenylglycine (DHPG) into the PVN caused an increase in mABP, 
LSNA and HR in both strains of animal.  This effect was attenuated with 
blockade of either mGluR1 or mGLuR5.  Also, blocking NMDA receptors in the 




PVN via microinjection of AP5, markedly reduced the sympathoexcitatory 
response evoked by agonism of group 1 mGluRs, suggesting that NMDA 
receptors mediate this response (Li and Pan, 2010). Figure 5 summarises these 
findings.    
Li et al. went on to study NMDA receptor involvement in more detail in cultured 
neurons harvested from the PVN of WKY rats and SHRs where they blocked 
post-synaptic NMDA receptors via intracellular dialysis of MK-801, an open-
channel blocker of the receptor, and found that this abolished the increase in 
neuronal firing caused by application of DHPG, supporting post-synaptic 
NMDA receptors in the sympathoexcitatory effect of mGluR5 stimulation in the 
PVN.  The fact that excitatory post-synaptic current was not affected by 
application of DHPG further supports this, as it shows that mGluR5 does not 
mediate glutamate release from presynaptic neurons.  Importantly, they also 
showed that mGluR5 blockade had the same effect in animals that had their 
blood pressure lowered by celiac ganglionectomy as in animals that underwent 
sham surgery, suggesting that mGluR5 over activity in SHRs is contributing to 
hypertension, rather than manifesting as a response to it.  They found further 
evidence for this using western blotting and qPCR on tissue homogenates to 
show that mGluR5 was upregulated in the PVN and RVLM of SHRs compared 








Group 1 mGluR antagonist 
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Sympathetic outflow 
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Figure 5: Schematic outlining the evidence obtained by Li and Pan’s microinjection experiments (Li and Pan, 
2010), which suggests mGluR5 is present in the PVN and plays a role in the control of sympathetic outflow. 
mGluR: Metabotropic glutamate receptor, PVN: Paraventricular nucleus of the hypothalamus, NMDA: N-
methyl-D-aspartate receptor.  





The Autonomic Nervous System Modulates the Immune System: 
The lymphoid organs are heavily innervated by the autonomic nervous system. 
In the 1960s, it was observed that vagus nerve stimulation increased Ach release 
from the spleen (Brandon & Rand, 1961; Leaders & Dayrit, 1965).  Watkins et 
al. (1995) later discovered that IL-1β administered intra-abdominally would only 
cause fever if the vagus nerve was intact, meaning that sensory afferents transmit 
information regarding the presence of inflammatory molecules to the CNS.  
Niijima et al. (Niijima et al., 1991; Niijima, 1995, 1996) recorded action 
potentials travelling from the liver to the brainstem via the vagus nerve and 
discovered that this afferent signal to the brainstem triggered efferent 
neurotransmission descending to the spleen and thymus.  They showed that 
intra[hepatic]portal injection of IL-1β dose-dependently increased afferent 
activity in the hepatic branch of the vagus nerve and caused reflex efferent 
activity in the splenic (sympathetic) and vagal thymic nerves.  This activity was 
eliminated in hepatic vagotomised rats nor was it observed if the cytokine was 
administered into the systemic venous circulation.  From this Niijima et al. 
concluded that there were sensors for IL-1β in the hepatic portal blood and these 
relayed information regarding IL-1β to the CNS where descending activity was 
activated (Niijima et al., 1996).   
In the early 2000s, it was observed that CNI1493, a cytokine blocker, was only 
able to block cytokine release if the vagus nerve was intact (Borovikova et al., 
2000a) and that in animals with induced endotoxaemia, directly stimulating the 
vagus nerve reduced TNFα synthesis (Borovikova et al., 2000b).   




This evidence from Watkins et al., Niijima et al., Borovikova et al. and other 
groups was taken together and reviewed by Tracey in Nature in (2002), when the 
elucidation of neuronal immunological reflexes maintaining homeostasis was 
considered revolutionary.  Tracey wrote that this reflex was mediated by the 
parasympathetic system (Tracey 2002) but this has since been disproven.  The 
afferent arm of the reflex is humoral and the efferent is sympathetic as outlined 
below. 
Overview of the Inhibitory Inflammatory Reflex: 
Inflammation is a critical response to injury or infection.  The mobilisation of 
innate immune cells along with their molecular mediators and their subsequent 
localisation to the damaged site is the initial phase of healing and pathogen 
neutralisation.  However, if inflammation is excessive or if it is not contained 
within the locus of the noxious stimuli that initiated it, severe, possibly fatal, 
tissue damage can occur.  The autonomic nervous system provides rapid 
regulation of the inflammatory response (Waldburger & Firestein, 2010).  Its 
action is complimentary to the slower paracrine signalling by regulatory T cells 
(Treg), immunosuppressive T cells which downregulate proliferation of effector T 
cells and the production of pro-inflammatory cytokines in order to curtail the 
immune response. 
The first way in which the autonomic nervous system can regulate inflammation 
is via the hypothalamic–pituitary–adrenal axis (HPA), through which a 
signalling cascade results in the release of glucocorticoids from the adrenal 
cortex, which suppress production of pro-inflammatory cytokines (Besedovsky 
et al., 1986).  This action is global as the glucocorticoids are released into the 
general circulation. 




Activation of the HPA axis occurs as a result of humoral messengers such as 
inflammatory cytokines and prostaglandins acting in the brain (Besedovsky et 
al., 1986; Turrin & Rivest, 2004; Saper et al., 2012).  The preoptic area, a region 
of the hypothalamus, is of particular significance for this action.   
The other way in which the sympathetic nervous system can control 
inflammation is via its innervation of the spleen. The spleen is the main source of 
TNFα (Huston et al., 2006) resulting from injection of lipopolysaccharide (LPS), 
an endotoxin produced by bacteria and commonly used by researchers to 
provoke an inflammatory response.  The efferent arm of the cholinergic anti-
inflammatory pathway innervates this organ (Figure 6). 
In response to detection of LPS, neurones in the greater splanchnic nerve are 
stimulated.  This efferent activity stimulates adrenergic splenic neurons situated 
in the celiac ganglion, which project to the spleen and terminate in structures 
analogous to synapses in the white pulp (Rosas-Ballina et al., 2011).  NA 
released from the splenic efferents binds to β2 receptors on certain T cells 
expressing choline acetyltransferase, a crucial enzyme involved in Ach synthesis 
(Rosas-Ballina et al., 2011). 
Ach produced by splenic T cells binds to α7 nAChR on macrophages in the non-
lymphoid red pulp and in the marginal zone of the spleen (Rosas-Ballina et al., 
2011).  Activation of this receptor suppresses NF-κB (Wang et al., 2003), 
resulting in a down-regulation of cytokine synthesis, thereby reducing 
inflammation.   Mice lacking α7 nAChR are extremely susceptible to generating 
an inflammatory response as a result of endotoxaemia or adjuvant arthritis 
(Wang et al., 2003; van Maanen et al., 2010), demonstrating the critical role for 
this receptor in the control of inflammation. 




MacNeil et al., (1997) showed that ICV injection of indomethacin, an inhibitor 
of prostaglandin synthesis, blocked the increase in activity of the splenic nerve 
that normally occurs as a result of intravenous injections of LPS.  This 
demonstrated that prostaglandin acting in the CNS mediated the reflex activation 
of the splenic nerve.  Partly due to this work, it is thought that along with the 
HPA, the afferent arm of the cholinergic immune reflex is also humoral, but it 
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Figure 6: Overview of the cholinergic immune reflex:  Immune challenge (e.g. Lipopolysaccharide) causes release of humoral 
factors which stimulate neurones within the central nervous system, causing the firing of action potentials that  are sent via 
the neurones of the greater splanchnic nerve,  exciting (via the celiac ganglion) neurones innervating the spleen and adrenal 
gland.  This downregulates synthesis of TNFα via release of glucocorticoids from the adrenal gland and cholinergic inhibition 
of NFκB in the spleen. LPS: Lipopolysaccharide, CNS: Central Nervous system, TNFα: Tumor necrosis factor alpha 




The Adaptive Immune Response: 
In a normal adaptive immune response, antigen-presenting cells collect non-self 
proteins (e.g. those of viruses) and process them into peptides such that the 
immunogenic region of these proteins can be externalised and presented to T-
cells for potential recognition by unique receptors. 
Helper T cells are mostly activated by antigen presentation from dendritic cells.  
These antigen-presenting cells process antigens in phagosomes (specialised 
vesicles containing hydrolytic enzymes) and present the antigenic peptide within 
major histocompatibility complex II (MHC II).  The cells then migrate to 
secondary lymph organs (e.g. lymph nodes and the spleen) where they await an 
interaction with a T cell that has a receptor that is complementary to the peptide 
in question.  This interaction, along with other interactions between co-
stimulatory molecules expressed on the antigen-presenting cell and the T cell, 
begin an immunological signalling cascade resulting in effector T cell 
proliferation and differentiation, cytokine production, evacuation from secondary 
lymph organs, mobilisation into the blood stream and homing to sites of 
inflammation in the periphery via chemotaxis.  Dendritic cells are not the only 
antigen-presenting cells.  Other cells with this ability include macrophages, B-
cells and activated endothelial cells (Pober et al., 2001; Gelin et al., 2009). 
Helper T cells interact with B cells and promote the production of antibodies (Jr 
et al., 2001).  Cytotoxic T cells do not interact with B cells and are not involved 
in promoting antibody synthesis but are able to produce molecules such as 
granzymes and perforin both of which destroy other cells directly.  They also 
secrete cytokines that orchestrate the immune response. 




Helper T Cell Activation, Differentiation and the Resulting Cytokine 
Profile: 
Helper T cells activation results in their differentiation into TH1, TH2 and the 
more recently discovered TH17 subtypes, each with the capability to secrete 
different combinations of cytokines.   Depending on the invading pathogen, 
helper T cells will differentiate into the relevant subtype in order to facilitate the 
production of appropriate cytokines required for an effective response.   
TH1 cell differentiation is triggered by IL-2 and the cells produce IFN-γ, IL-2 
and TNF-α.  These cells are involved in inflammation resulting from invasion of 
pathogens such as viruses, intracellular bacteria and protozoa.  They are also 
involved in auto-immune pathology (Notley et al., 2008; Fletcher et al., 2010). 
Their cytokines target macrophages, CD8+ cytotoxic T cells, IgG B cells and 
dendritic cells.  IFN-γ is able to inhibit viral replication directly, activates the 
phagocytic functions of macrophages and causes nitric oxide synthase to produce 
cytotoxic ROS.  It also increases expression of MHC class II in dendritic cells in 
order to facilitate antigen presentation. 
The TH1 subset is thought to be involved in hypertension as it is involved in 
other inflammatory conditions.  The T cells in atherosclerotic plaques are TH1-
polarised (Gisterå & Hansson, 2017).  Enteracept, which inhibits the TNF-α 
secreted by TH1 cells, blocks vascular dysfunction and hypertension caused by 
ANG II infusion (Guzik et al., 2007).  Chronic enteracept treatment prevents the 
development of hypertension in fructose-fed rats (Tran et al., 2009).  Infusion of 
ANG II increases differentiation of helper T cells to the TH1 subtype (Shao et al., 
2003).  This is known as TH1 polarisation.  Human patients with essential 
hypertension have elevated levels of circulating interferon-gamma-inducible 




protein 10 (Stumpf et al., 2011), which is indicative of TH1 polarisation of helper 
T cells, since this, as its name suggests, is induced by IFN-γ, which is a hallmark 
secretion of TH1 cells.   
TH2 cells specialise in combating extracellular parasites such as helminths and 
are involved in allergic reactions (Lloyd & Hessel, 2010).  Differentiation of 
CD4+ T cells into this subtype is triggered by IL-4 and this cytokine is produced 
by TH2 cells in a positive feedback loop in order to amplify differentiation.  The 
TH2 subtype also secretes interleukins 5, 9, 10 and 13.  Their effector cells are B 
cells (production of IgE antibodies), as well as mast cells, basophils and 
oesinophils.   
TH17 cells produce IL-17, IL-21 and IL-22.  IL-17 is also produced by NK cells, 
mast cells and neutrophils (Witowski et al., 2004).  Chronic infusion of ANG II 
markedly increases the percentage of helper T cells of the TH17 subtype and 
increased vascular levels of IL-17 (Madhur et al., 2010).  Genetically modified 
mice lacking IL-17 exhibit reduced vascular dysfunction and a lesser 
hypertensive response when infused with ANG II (Madhur et al., 2010). Also, 
the vascular accumulation of leukocytes normally seen as a result of ANG II 
infusion was all but eliminated in these animals.  This evidence strongly 
implicates IL-17 and thereby TH17 cells in hypertension.  Daily intraperitoneal 
injection of IL-17 promotes endothelial dysfunction and hypertension in mice 
(Nguyen et al., 2013).  IL-17 is a major contributor to the pro-inflammatory 
cytokine milieu that promotes vascular dysfunction and thereby hypertension.   
Activated helper T cells produce pro-inflammatory cytokines and contribute to 
hypertension.  Regulatory T cells, which act to suppress the immune response by 




dampening induction of effector (activated) T cells and T cell proliferation, 
protect against hypertension in rats (Viel et al., 2010). 
The Sympathetic Nervous System Modulates Helper T Cell 
Differentiation and Promotes a Pro-Inflammatory, Pro-Hypertensive 
Cytokine Profile in Hypertension: 
Both primary (thymus and bone marrow) and secondary (spleen and lymph 
nodes) lymphoid organs receive sympathetic innervation and almost all cells of 
both the innate and adaptive immune systems express receptors for 
neurotransmitters and neurohormones (Nance & Sanders, 2007).  Immune cells 
express adrenergic β receptors.  T lymphocytes preferentially express the β2 
subtype but β1 are also expressed (Sanders & Straub, 2002).  Through these 
receptors, the sympathetic nervous system is able to modulate the immune 
response by affecting clonal expansion, cell migration and cell trafficking 
(Sanders & Straub, 2002; Steinman, 2004; Bellinger et al., 2008). 
NA can modulate polarisation of naïve helper T cells to the TH1 subtype, 
resulting in either an increase or decrease in polarisation depending on the 
presence of other cytokines (Swanson et al., 2001).  These effects are prevented 
by blockade of β2 adrenorecptors (Swanson et al., 2001). 
Mice that are deficient in dopamine β hydroxylase, an enzyme that catalyses the 
conversion of dopamine into NA, exhibit impaired TH1 polarisation when 
infected with listeria monocytogenes, an intracellular bacterial pathogen to which 
TH1 polarisation is the appropriate response. (Alaniz et al., 1999). 
Chronic systemic infusion of catecholamines causes atrophy of the spleen and 
reduces the number of T cells it contains.  It also decreases the percentage of 




cells of the cytotoxic and regulatory subsets (Harris et al., 1995).  These effects 
were blocked by propranolol, a β adrenoreceptor antagonist. 
Helper T cells were activated and T cell infiltration into the aorta was increased 
by chronic infusion of NA (Marvar et al., 2010).  
Patients with chronic heart failure who were treated with beta-blockers (β 
adrenoreceptor antagonists) or ACE (angiotensin converting enzyme) inhibitors 
had a decreased ratio of TH1/TH2 cytokines (Gage et al., 2004).  This means that 
modulating the effects of sympathetic outflow can affect the cytokine milieu and 
thereby regulate inflammation.  It is possible that the therapeutic effects of these 
drugs manifest partly as a result of immunomodulation in addition to their 
known effects on heart rate, blood volume, peripheral resistance etc.  
Reactive Oxygen Species in Hypertension: 
Previously thought to be exclusive to phagocytic cells of the innate immune 
system, T cells also produce reactive oxygen species (ROS), which eliminate 
pathogens (Rashida Gnanaprakasam et al., 2018). ROS are metabolites of 
oxygen that are able to either steal electrons away from other molecules (oxidise 
them) or donate electrons to them (reduce them).  One important ROS in 
cardiovascular physiology is superoxide.  This is formed by the one-electron 
reduction of molecular oxygen (Buettner, 2011).  This ROS has an unpaired 
electron in its outer orbit and as such it is deemed a radical.  Superoxide is 
important because of its versatility as it is able to both oxidise and reduce other 
physiological molecules (Buettner, 2011).  It is also a progenitor for other 
reactive oxygen species including the hydroxyl radical (HO.) (Buettner, 2011). 
Physiological levels of ROS in the vasculature are essential for endothelial 
homeostasis and smooth muscle cell contraction (Touyz et al., 2018).  However, 




overproduction of ROS or failure of normal elimination mechanisms (such as 
reduced superoxide dismutase, an enzyme that degrades superoxide) causes 
vascular dysfunction and disease via vascular remodelling.  This occurs as a 
result of direct damage to cells, lipid peroxidation, recruitment of immune cells, 
activation of metalloproteinases and deposition of extracellular matrix (Vara & 
Pula, 2014; Raaz et al., 2014; Konior et al., 2014). 
ROS are produced by: NADPH oxidase, uncoupled NO synthases, xanthine 
oxidases, cyclooxygenases and components of the mitochondrial electron 
transport chain (Granger & Kvietys, 2015).  The most important source of ROS 
relating to cardiovascular physiology is NADPH oxidase, which is largely found 
in phagocytic cells of the immune system but is also present in T cells (Jackson 
et al., 2004) and vascular endothelial cells, where it plays a functional role in 
normal cell signalling as well as pathophysiological activity (Burtenshaw et al., 
2017). 
ANG II, aldosterone and various cytokines all cause the production of ROS via 
activation of NADPH oxidase, which contributes to the generation of 
hypertension.  T cells possess AT1 receptors and ANG II stimulates T cell 
proliferation via these receptors (Nataraj et al., 1999).  The NADPH oxidase 
present in T cells becomes functional when T cells are activated (Jackson et al., 
2004), resulting in rapid ROS generation. 
ROS that are produced by NADPH oxidase have been shown to play a crucial 
role in hypertension.  Mice lacking p47phox , a critical component of NADPH 
oxidase, exhibit a severely blunted hypertensive response to infusion of ANG II.  
In this study, superoxide production in vascular smooth muscle cells and the 




endothelium was markedly increased following ANG II infusion in WT mice, 
but not in the p47phox -/- animals (Landmesser et al., 2002). 
Similarly, Matsuno et al. demonstrated that unlike WT controls, mice lacking 
Nox1, another component of NADPH oxidase, did not exhibit the increased 
vascular superoxide production or increase in blood pressure expected as a result 
of ANG II infusion (Matsuno et al., 2005).  In contrast, mice overexpressing 
Nox1 were sensitised to ANG II-induced hypertension (Dikalova et al., 2005). 
Nitric oxide (NO) is produced by a nitric oxide synthase enzyme located in the 
vascular endothelium (i.e. eNOS) and acts as a potent vasodilator via a signalling 
cascade within vascular smooth muscle cells.  Superoxide reacts with 
endogenous NO, producing inactive nitrite and nitrate, depriving the vasculature 
of a crucial anti-hypertensive mechanism (Gryglewski et al., 1986).  This is one 
of a variety of ways in which ROS are known to promote hypertension.   
Production of superoxide results in the formation of highly reactive γ-
ketoaldehydes from the H2-isoprostane pathway (Davies et al., 2004).  γ-
ketoaldehydes affect protein function by adducting to lysine residues (oxidative 
modification) and causing excessive crosslinking.   Formation of such adducts 
has been observed at an increased rate in conditions with which oxidative stress 
is associated (Salomon et al., 2000; Roychowdhury et al., 2009; Davies et al., 
2011). As a result of hypertensive challenges, these adducts accumulate in 
dendritic cells and cause increased production of pro-inflammatory cytokines 
such as IL-6, IL-1β, and IL-23 (Kirabo et al., 2014), as well as increased 
expression of co-stimulatory proteins that are involved in activation of T-cells.  
These changes in dendritic cells result in the proliferation of T cells (especially 
cytotoxic T cells), their production of IFN-γ , IL-17 and TNFα and as a result, 




hypertension (Kirabo et al., 2014).  These pathophysiological consequences of 
hypertensive challenges are alleviated by compounds that scavenge γ-
ketoaldehydes (Kirabo et al., 2014). 
In addition to this known pro-inflammatory, pro-hypertensive activity of ROS, it 
has been hypothesised (Harrison et al., 2011) that oxidative stress could result in 
the modification of endogenous proteins such that they are no longer recognised 
as self (i.e. ‘neoantigen’ formation) and that this could lead to a chronic 
pathological auto-immune response which contributes to the generation of 












This hypothesis is important to this thesis and will be discussed more later.   
 
Figure 7:  Schematic outlining the neoantigen hypothesis of hypertension (Harrison et al., 2011). In a 
classical immune response, antigen-presenting cells such as dendritic cells recognise the non-self proteins  
(antigens) expressed by pathogens and activate T cells, resulting in appropriate and useful inflammation.  
Harrison et al. hypothesise that interactions between endogenous proteins and reactive oxygen species 
result in the modification of said proteins such that they are no longer recognised as self and thereby cause 
pathological inflammation via inappropriately triggering the classical inflammatory pathway.  These 
modified endogenous proteins are deemed ‘neoantigens’. 




T Cells Play a Critical Role in Hypertension: 
Many studies have demonstrated a role for the adaptive immune system and 
specifically T cells in hypertension: 
• Svendsen demonstrated, using a DOCA-salt model of hypertension, that 
although the initial phase of hypertension was unchanged, the chronic 
phase was blunted in animals that had their thymus removed (Svendsen, 
1976). 
• Systemic administration of activated T cells to patients with metastatic 
melanoma of the lung increased blood pressure (Balsari et al., 1986).  
Preeclampsia (pregnancy-induced hypertension) is associated with 
immune system activation (Minagawa et al., 1999). 
• Suppression of the adaptive immune system lowers blood pressure in 
animal models of hypertension and in humans.  Blood pressure can be 
reduced in SHRs by reducing immune cell infiltration into the kidneys 
(Rodríguez-Iturbe et al., 2002) and the use of corticosteroids to suppress 
the immune system protects against ANG II-induced renal damage in 
rats (Muller et al., 2002).   
• AIDS patients, who have reduced helper T cells have a significantly 
lower incidence of hypertension as a population than population-
matched controls whereas anti-retroviral therapy increases the rate of 
those with hypertension to that of the control population (Seaberg et al., 
2005). 
• Mycophenolate mofetil (an immunosuppressant normally used for 
preventing transplant rejection) prevented renal damage and lowered BP 
in a rat model of salt-sensitive hypertension (Tian et al., 2007).  




Hypertensive patients who were prescribed the same drug for the 
purpose of treating severe auto-immune skin conditions, saw their blood 
pressure lowered as a side effect (Herrera et al., 2006).   
 
In 2007, Guzik et al. clearly demonstrated an essential role for T cells, in the 
genesis of hypertension (Guzik et al., 2007).  They showed that the expected 
hypertension caused by chronic low-dose ANG II infusion is markedly reduced 
in mice in which the recombinase-activating gene 1 has been genetically deleted 
(RAG-1-/- mice).  As a result, these animals lack both T and B cells, but 
expression of vascular AT1 receptors was shown to be normal, as was the 
vasoconstrictor response to acute high dose ANG II administration (Guzik et al., 
2007).  This suggests that the reduced hypertensive response to ANG II 
challenge in the RAG-1-/- mice was not due to signalling problems or limited 
receptor availability but loss of the AT1R response mediated by T cells.  Guzik 
also found reduced vascular superoxide production in RAG-1-/- mice even during 
ANG II infusion.  Further, ANG II infusion had a minimal effect on 
endothelium-dependent vasodilation in RAG-1-/- mice and the vascular 
hypertrophy commonly associated with hypertension was significantly reduced 
in these animals compared to in the WT (Guzik et al., 2007).  Vascular 
hypertrophy can be secondary to or exacerbated by hypertension, but ANG II can 
directly cause vascular smooth muscle cell hypertrophy independently of 
hypertension/haemodynamics (Morishita et al., 1994; Cai et al., 2003) and it is 
the attenuation of this direct effect in RAG-1-/- mice that is evident in the Guzik 
study.   These findings demonstrate that several major consequences of ANG II-
induced hypertension are mediated via lymphocytes.   Marvar et al. showed that 




RAG-1-/- mice are also protected from stress-induced hypertension and the T cell 
activation and vascular inflammation that accompany it (Marvar et al., 2012). 
Crucially, Guzik et al. found that adoptive transfer of T but not B lymphocytes 
into RAG-1-/- mice restored hypertension and vascular superoxide production 
caused by ANG II infusion to the same levels observed in WT controls (Guzik et 
al., 2007) and Marvar et al. found that T cell restoration restored the 
hypertensive response to stress (Marvar et al., 2012).  Also, Ach-mediated 
vasodilation was impaired in RAG-1-/- mice after T cells were restored (Guzik et 
al., 2007).  These findings clearly implicate T cells specifically in the genesis of 
hypertension and the associated vascular dysfunction and superoxide 
overproduction. 
The hypertension caused by ANG II infusion can be blocked by antagonism of 
AT1 receptors.  Guzik et al. (2007) demonstrated that the AT1 receptors present 
on T cells are partially responsible for the generation of hypertension resulting 
from chronic ANG II infusion, since adoptive transfer of T cells from AT1-/- 
mice into RAG-1-/- mice did not fully restore hypertension in the RAG-1-/- mice 
to levels observed in WT controls.  The same effect was observed when T cells 
from mice lacking the p47phox subunit of NADPH oxidase were transferred into 
RAG-1-/- mice (Guzik et al., 2007).  This provides further evidence that ANG II 
is able to activate NADPH oxidase via AT1 receptors and that superoxide 
production by T cells is pro-hypertensive.  
Not only do T cells promote hypertension as a result of systemically produced 
ANG II (via ACE in the lungs) but they also have their own internal renin-
angiotensin system (Jankowski et al., 2005). Thus, T cells produce their own 
ANG II.  The majority of AT1 receptors expressed by T cells are cytosolic (Hoch 




et al., 2009) and ANG II produced by the cells is involved in intracrine as well as 














T cell production of TNFα and IFNγ is increased following 2 weeks of ANG II 
infusion in WT but not in p47phox-/- mice (Guzik et al., 2007), showing that both 
cytokines are produced as a result of NADPH oxidase activity stimulated by 
ANG II.  Etantercept (an inhibitor of TNFα) prevented the hypertensive response 
to ANG II infusion in WT mice and vastly reduced the increase in vascular 
superoxide production (Guzik et al., 2007).  A neutralising anti-IFNγ antibody 


















Figure 8:  Schematic showing the angiotensin system within T cells and outlining the relationship between ANG II, 
NADPH oxidase, TNFα, ROS and hypertension.  Agt = Angiotensinogen, ANG I = Angiotensin I, ANG II = Angiotensin II, 
ACE = Angiotensin converting enzyme, AT1R = Angiotensin II receptor type 1, TCR= T cell receptor, TNFα = Tumor 
necrosis factor alpha. 




did not have a significant effect on either (Guzik et al 2007), suggesting a critical 
pro-hypertensive role for TNFα in particular. 
It is important to note that the pathway outlined above is not the only source of 
TNFα or superoxide produced by T cells.  ACE inhibitors, angiotensin receptor 
antagonism and scavenging of superoxide only reduced TNFα production by 
between 30-60% (Hoch et al., 2009), meaning that the cells have alternative 
means of production that are independent of ANG II and account for a 
substantial proportion of their output of these products. 
Systemic administration or injection of TNF-α into various key nuclei involved 
in blood pressure control such as the RVLM and the PVN increases sympathetic 
nerve activity and blood pressure in rats (Zhang et al., 2003).  The fact that either 
central or peripheral administration elicits these effects shows that cytokines can 
act upon central signalling pathways either via the CVOs or perhaps via soluble 
mediators such as prostaglandins (Zhang et al., 2003).  It may also be the case 
that cytokines that cannot normally cross the BBB are able to do so in 
hypertension due to the disruption of the barrier (Shi et al., 2014). 
Other cytokines have been shown to affect sympathetic output as well.  IL-6 
microinjected into the NTS attenuates baroreceptor function in rats (Takagishi et 
al., 2010) and intracerebroventricular administration of the same cytokine 
increases splenic nerve activity (Helwig et al., 2008).  Monocyte chemoattractant 
protein-1 is upregulated in the NTS of SHR (Waki et al., 2008).  IL-1β 
administered centrally increases splenic, adrenal and renal sympathetic outflow 
(Niijima et al., 1991).   
TNF-α, IL-6 and IL-1β are all elevated in the SHR, along with vascular 
inflammation.  Candesartan, an AT1 receptor blocker, lowers levels of all three 




cytokines as well as vascular inflammation and BP (Ando et al., 2004; Sanz-
Rosa et al., 2005). 
TNF-α and IL1-β cause perivascular macrophages at the BBB to release 
prostaglandin E2, which is soluble and enters the brain parenchyma, stimulating 
neurons in the PVN and increasing sympathetic drive (Felder, 2010).  Both 
cytokines increase the rate of neuronal firing by activating NF-κB (Kang et al., 
2009).  Intracerebroventricular infusion of pyrrolidine dithiocarbamate (an NF-
κB inhibitor) reduces ANG-II induced hypertension and pro-inflammatory 
cytokines in the PVN (Kang et al., 2009). 
TNF-α, C-reactive protein, monocyte-chemoattractant protein 1, IL-6 and 
various adhesion molecules such as P-selectin and ICAM-1 have been shown to 
be elevated in hypertensive patients (Koh et al., 2003; Fliser et al., 2004) and 
drugs that inhibit the RAS system reduce these as well as BP (Fliser et al., 2004; 
Koh et al., 2003).  Receptors for cytokines are located in many cell types in the 
brain including neurones, astrocytes and microglia (Utsuyama & Hirokawa, 
2002).  Also, cytokines are able to activate inducible nitric oxide synthase and 
the NO produced can diffuse to adjacent tissues and affect ion-channel function, 
resulting in modulation of neuronal activity (Li et al., 2004) 
These studies provide evidence that cytokines produced by T cells, or the 
phagocytic cells attracted by them can promote hypertension directly, as well as 
by promoting pro-hypertensive behaviour of leukocytes such as endothelial 
binding/extravasation and ROS production. 
It has been noted that in hypertension, T cells accumulate in the kidneys 
(Harrisson et al., 2011).  These increase sodium retention and are responsible for 
causing vascular dysfunction through the release of pro-inflammatory cytokines  




(Trott & Harrison, 2014).  Wilcox proposes that ROS produce a NO deficiency 
in the kidney, leading to increased sodium retention and thereby hypertension via 
increased total blood volume (Wilcox, 2005) 
Activation of T Cells is Driven by Sympathetic Outflow Resulting 
From ANG-II Induced Oxidative Stress in the CVOs: 
Owing to the incomplete formation of the BBB at the CVOs, they are exposed to 
circulating ANG II and this results in increased production of ROS, especially in 
the subfornical organ (Zimmerman et al., 2004).  Zimmerman et al. report that 
adenoviral-mediated delivery of cytoplasmically targeted superoxide dismutase 
selectively to this site, eliminates the hypertension invoked as a result of infusion 
of ANG II into the CNS as well as the increased production of superoxide in the 
subfornical organ that was associate with it.   
(Lob et al., 2010) produced a genetically modified mouse in which they were 
able to acutely delete superoxide dismutase in the CVOs.  Deletion of the 
enzyme raised BP by 20mmHg and markedly sensitised the animals to 
hypertension caused by low-dose ANG II infusion.  The vascular inflammation 
associated with ANG II infusion was significantly increased in these animals, as 
was the percentage of T cells of an activated phenotype.  These effects were 
associated with an increase in sympathetic outflow (Lob et al., 2010).  The same 
group also acutely deleted P22phox (an essential subunit of NADPH oxidase) in 
the same region and the same effects were observed in response to ANG II 
infusion as with superoxide dismutase deletion (Lob et al., 2013), confirming 
that increased ROS signalling in the subfornical organ mediates increased 
sympathetic nerve activity and lymphocyte activation evoked in response to 
ANG II in the CNS.  These findings fit with the evidence presented by Ganta et 




al., who found that intracerebroventricular administration of ANG II increases 
splenic expression of pro-inflammatory cytokines responsible for T cell 
activation and that this effect was blocked by lesioning of the splenic nerve 
(Ganta et al., 2005). In keeping with this is the fact that intracerebroventricular 
injection of a superoxide scavenger reduces blood pressure and sympathetic 
drive in a rat model of salt-induced hypertension (Fujita et al., 2012).  Further, 
lesioning of the anteroventral third cerebral ventricle, a region that includes the 
subfornical organ, blocks ANG II induced hypertension together with the 
associated peripheral T cell activation and vascular inflammation (Marvar et al., 
2010). 
There is evidence that inflammation caused by ANG II also occurs downstream 
of the CVOs, in the PVN.  Kang et al. showed that pro-inflammatory cytokines, 
ROS and NF-κB activation are increased in the PVN in response to intravenous 
ANG II infusion (Kang et al., 2009).  These effects were blocked by central (3rd 
ventricle) co-administration of compounds that blockade AT1 receptors, NF-κB 
and superoxide.  These interventions also restored BP and sympathetic activity to 
normal in ANG II infused rats (Kang et al., 2009), demonstrating the importance 
of this signalling in ANG II-induced hypertension.  Further, 
intracerebroventricular administration of minocycline (an anti-inflammatory 
antibiotic) significantly reduced BP, cardiac hypertrophy and plasma NA in 
response to ANG II infusion in rats (Shi et al., 2010).  This was associated with 
reduced microglia activity and mRNAs for a variety of pro-inflammatory 
cytokines in the PVN.  Overexpression of the anti-inflammatory IL-10 had the 
same effect and administration of the pro-inflammatory IL-1β, the opposite (Shi 
et al., 2010).  This demonstrates a role for microglia and pro-inflammatory 
cytokines in ANG II-induced hypertension. 




Leukocyte-Endothelial Interactions and Pathological Leukocyte 
Extravasation in the Brain: 
Evidence has accumulated supporting the notion that inflammation in the 
microvasculature of the brain contributes to hypertension. 
Ando et al. showed that AT1 receptor expression was increased in endothelial 
cells of the brain microvasculature of SHRs (Ando et al., 2004).  The 
pathological vascular hypertrophy associated with hypertension was reversed by 
chronic administration of candesartan, an AT1 receptor antagonist.  Further, 
following the candesartan treatment, ICAM-1 (adhesion protein involved in 
immune cell recruitment) expression was decreased and as a result of this, 
macrophage infiltration into brain vessels of the SHRs was reduced (Ando et al., 
2004).  This study provides evidence that inflammation in the brain 
microvasculature results from the activity of the sympathetic nervous system and 
that blockade of this activity can mitigate hypertension.   
ANG II promotes leukocyte-endothelial interaction, which promotes 
inflammation (Zhang et al., 2010). Junctional adhesion molecule-1 (JAM-1) 
forms the tight junctions between adjacent endothelial cells and is considered to 
be a constituent component of the BBB (Huber et al., 2001).  It is involved in the 
facilitation of leukocyte transmigration (Del Maschio et al., 1999) and is 
associated within endothelial cells of the brainstem microvasculature.  JAM-1 
(Waki et al., 2007), and glycoprotein precursor 39 (gp39) (Waki et al., 2008) 
expression is increased in the NTS of SHR compared to normotensive controls,  
both in juveniles prior to the development of HT and in adults when it is fully 
established.  This indicates a causative role for these proteins.  Over-expression 
of JAM-1 in the NTS of normotensive WKY rats causes hypertension, localised 




inflammation and an increase in sympathetic outflow to the peripheral 
vasculature (Waki et al., 2008), further evidencing the pro-hypertensive role for 
JAM-1. 
Adhesion of leukocytes to vascular endothelial cells is increased in the brainstem 
microvasculature of SHRs compared to normotensive WKY rats (Waki et al., 
2007) and the same phenomenon was demonstrated previously in the peripheral 
vasculature (Fukuda et al., 2004).  The induced HT and sympathetic activity 
increase resulting from JAM-1 overexpression occurred alongside leukocyte 
adhesion to the vascular endothelium which was not occurring prior to the 
intervention (Waki et al., 2007).  It is likely that leukocyte invasion into these 
vessels causes the observed HT.  ROS and some of the cytokines that are 
produced by leukocytes are able to cross the BBB (Banks, 2005).  
Monocyte chemoattractant protein 1 (a pro-inflammatory chemoattractant) 
expression is increased in adult SHRs compared to normotensive controls.  This 
is not observed in normotensive, juvenile SHRs (Waki et al., 2008).  This may 
occur as a result of pathological signalling resulting from invasion of the vessels 
by leukocytes due to the genetically pre-determined increased expression of 
JAM-1 in these animals.  Leukocyte adhesion to endothelial cells in the brain 
microvasculature has been shown to cause the production of ROS and cytokines 
that pass into nearby neurones. Based on this, it may be the case that increased 
JAM-1 expression in SHRs causes disputation to the normal function of the 
cardiovascular neuronal networks in the NTS and other brainstem nuclei via 
pathological signalling resulting from the invasion of leukocytes that is 
facilitated by JAM-1.  ANG II, circulating at higher levels in hypertensives, 
could exacerbate this. Zhang et al. reported in 2010 that ANG II chronically 




increases the permeability of the BBB via oxidative stress and increases 
inflammation in the brain microvasculature (Zhang et al., 2010). Microglial 
cells, a type of CNS-specific macrophage, are activated in hypertension.  When 
activated, microglia produce cytokines and ROS, which damage the BBB 
(Yenari et al., 2006). This can be inhibited by minocycline, which lowers BP 
(Shi et al., 2010).  The integrity of the BBB is compromised in hypertension and 
this probably works to maintain the condition by facilitating inflammation of the 
brain parenchyma.   
Poor perfusion of the brainstem specifically may be a cause of hypertension.  
Naragchi et al. showed that patients with essential hypertension had 
neurovascular compression at the left ventrolateral medulla (Naraghi et al., 
1992).  The RVLM contains neurons that are sensitive to hypoxia (Wang et al., 
2001) and as such, poor perfusion of these neurons could result in an increase in 
sympathetic activity in order to raise blood pressure globally and restore 
adequate perfusion of the brain.  This has been referred to as the ‘selfish brain 
hypothesis’ of hypertension and is based on the early work of Harvey Cushing, 
who, in 1901, demonstrated an increase in arterial pressure caused by increased 
intracranial pressure (and thereby reduced brain perfusion) in dogs (Cushing, 
1901).  This was deemed the Cushing response.  More recently Braga et al. 
showed that the spinal cord of spinalised rats is able to produce 
sympathoexcitation in response to ischemia, demonstrating that the Cushing 
response is not limited to the pontomedullary structures of the brain (Braga et al., 
2007). 
Juvenile (normotensive) SHRs have narrower vertebral and basilar arteries than 
WT animals (Paton et al., 2007). Dickinson and Thompson found narrowed 




vertebral arteries in cadavers of patients that had essential hypertension and were 
unable to determine whether this was a cause or result of hypertension 
(Dickinson & Thomson, 1960).  The findings of Paton et al. would suggest that 
congenital malformations of arteries supplying blood to the brain may predispose 
individuals to the development of hypertension via a Cushing response i.e. BP is 
increased in order to overcome hypoperfusion of the brain parenchyma.  This is 
backed up by evidence that cerebral vascular resistance is increased in SHRs vs 
normotensive controls (Oseka & Koźniewska, 1997) yet brainstem blood flow is 
the same (Granstam et al., 1998):  It is likely that ischemia in the brain, 
exacerbated by leukocytes, evokes a Cushing response, causing or contributing 
to systemic hypertension.  The increased sympathetic activity resulting from this 
contributes to further pro-hypertensive activity of leukocytes as explained 
previously. 
 
Leukocytes Promote Hypertension by Increasing Haemodynamic 
Resistance in the Microvasculature: 
Circulating monocytes and neutrophils that bind to the vascular endothelium are 
prothrombogenic (Gorbet & Sefton, 2004).  It is possible that this could result in 
local hypoxia as a result of reduced vessel patency or complete occlusion of 
capillaries.  It is also the case that owing to their relatively large size and 
structural rigidity compared to erythrocytes, leukocytes increase haemodynamic 
resistance in capillaries with single file cells (Helmke et al., 1997, 1998) as they 
move through more slowly.  This effect does not depend on biochemical 
interactions with the endothelium and is entirely due to the physical mechanics 
of the cells.  It can be simulated with similarly proportioned biospheres (Helmke 




et al., 1997) which do not interact biochemically with the endothelium or other 
cells, thereby demonstrating the effect is due only to fluid dynamics. 
Leukocytes project few pseudopodia (cytoplasmic projections of the cell 
membrane) under conditions of shear stress (Fukuda & Schmid-Schönbein, 
2002; Fukuda et al., 2004) This allows the cells to remain more 
compact/spherical and flow more easily.  The presence of glucocorticoids 
inhibits the suppression of pseudopodia projection (Fukuda et al., 2004) and 
since SHRs express glucocorticoid receptors that are more sensitive and in 
greater numbers than in normotensive animals (Suzuki et al., 1995, 1996), 
circulating leukocytes of SHR project significantly more pseudopodia and this 
impairs their flow (Fukuda et al., 2004). Transfusing blood from SHR into WKY 
rats causes an increase in blood pressure due to impaired blood flow through the 
microvasculature as a result of impaired passage of leukocytes (Fukuda et al., 
2004).  Injecting WKY rats with SHR blood did not increase BP when 
leukocytes were removed from the blood (Fukuda et al., 2004).  The increased 
binding of leukocytes to the endothelium in the brainstem microvasculature 
observed by Waki et al. (2007) may not only contribute to hypertension as a 
consequences of leukocyte invasion into the vessels and brain parenchyma, but 
also by inhibiting blood flow through the lumen by increasing haemodynamic 
resistance. 
Summary of Neurogenic Hypertension Hypothesis: 
Increased circulating ANG II acts via AT1 receptors in the circumventricular 
organs to increase ROS production via stimulation of NADPH oxidase.  The 
resulting ROS activate microglia which causes production of more ROS as well 
as pro-inflammatory cytokines.  This stimulates neuronal activity and causes 




stimulation of downstream nuclei such as the NTS and the RVLM in the 
brainstem, driving sympathetic outflow up and thereby raising BP.  The increase 
in sympathetic activity also causes the release of catecholamines, which act via β 
adrenoreceptors to activate T cells, resulting in the release of further pro-
inflammatory cytokines and ROS, which promote vascular dysfunction in a 
variety of ways; blocking endothelium-dependent vasodilation through disabling 
NO, direct damage to endothelial cells caused by ROS, promoting leukocyte-
endothelial binding and invasion of the vessel wall and vascular remodelling 
(smooth muscle cell proliferation, deposition of extracellular matrix, vessel 
stiffening).  The resultant stiff vasculature raises the total peripheral resistance 
and vasodilation resulting from the baroreflex is less effective, which drives up 
BP further, resulting in more ANG II release (due to inflammation), more 
catecholamine release and release of other hormones that contribute to raising 
blood pressure such as ADH, aldosterone and adrenocorticotropic hormone, all 
of which modulate renal function, resulting in increased blood volume and 
thereby BP.  The vascular dysfunction also leads to organ hypoperfusion, which 
drives sympathetic outflow up further via afferents projecting to the CNS from 
hypoxic organs (Koeners et al., 2016).  
In the brain, the cytokine release, ROS and resulting pathological behaviour of 
leukocytes, facilitated by JAM-1, damages the integrity of the BBB, allowing 
activated leukocytes into the brain parenchyma and in key nuclei responsible for 
blood pressure control, such as the PVN, inflammation stimulates neurones that 
project down into the brainstem (NTS, RVLM) and ultimately stimulates further 
pathological sympathetic activity. 




Thus, a vicious cycle forms in which ANG II, inflammation, vascular 
dysfunction and organ hypoperfusion are all driving up sympathetic nervous 













The above scheme outlines how hypertension is maintained but not begun.  The 
initial trigger to begin this cycle is not known but yet-to-be-discovered genetic 
factors are a near certainty.  In addition, environmental and behavioural factors 
such as obesity, high salt intake, low levels of physical activity, insulin resistance 
and stress are known to be contributing factors and may be causal.  More 
environmental causes may also be identified in future. 
Vascular dysfunction and 
organ hypoperfusion Inflammation 
ANG II 
SNA 
Figure 9: Triangulation of neurogenic hypertension.  Positive feedback loops form between ANG II, inflammation and vascular 
dysfunction/organ hypoperfusion, creating an unresolving vicious cycle driving up sympathetic nerve activity. 




Reducing the sympathetic nerve activity at the centre of this scheme may 
constitute a novel anti-hypertensive strategy.  Patients afflicted with essential 
hypertension could benefit immensely from targeting the central driver of the 
condition rather than the secondary consequences of it, as current 
pharmacological interventions do. 
Objectives: 
The purpose of my project was to investigate the following hypotheses: 
• The use of compounds modulating the glutamatergic signalling of 
sympathetic nervous system activity could potentially constitute a novel 
antihypertensive strategy. 
• Hypertensives exhibit a pro-inflammatory immunophenotype compared 
to normotensives. 
• Modulation of glutamatergic signalling in rats will produce observable 












Chapter 2:  Using Immunohistochemistry to Localise 
mGluR5 in Nuclei Involved in Regulation of Blood 
Pressure  
Introduction: 
Compounds modulating mGluR5 have caused changes in blood pressure when 
administered systemically (Figure 10). 
 
Figure 10 shows pilot data from Eli Lilly and Company, demonstrating an 
increase in blood pressure caused by a single oral dose of LSN2814617, a 
positive allosteric modulator (PAM) of mGluR5.  This means the compound 
potentiates the response of the receptor to its endogenous ligand (glutamate) but 
is not an agonist.  Researchers at Lilly observed similar, though less pronounced 
effects with other mGluR5 PAMs, also administered systemically. 
Figure 10: Effect of a single oral dose of mGluR5 positive allosteric modulator LSN2814617 on the blood 
pressure in ferrets. n=4  unpublished data provided by Eli Lilly and company, 2009. 




The extent to which mGluR5 is present in key brain nuclei responsible for blood 
pressure control and the exact location within these nuclei is not fully 
understood.   
Li and Pan inferred the presence of mGluR5 in the PVN specifically in 2010 (see 
Chapter 1). In 2014, Li et al. used Western blots and qPCR to determine the 
presence of mGluR5 protein and mRNA in tissue homogenates from the PVN 
and RVLM in SHR and found mGluR5 was expressed in both nuclei and that 
expression was greater in SHR than it was in WKY (Li et al., 2014).  They found 
the protein and mRNA levels were much higher in the PVN and slightly higher 
in the RVLM of SHR compared to WKY rats. 
The hypothalamic paraventricular nucleus (PVN) is heavily involved in elevated 
sympathetic outflow and the development of hypertension. Selectively blocking 
mGluR5 significantly reduces the basal firing activity of spinally projecting PVN 
neurons in spontaneously hypertensive rats (SHRs), but not in normotensive 
Wistar-Kyoto (WKY) rats (Li et al., 2014). Antagonism of mGluR1 had no 
effect on the activity of PVN neurons in either strain in this study. The group I 
mGluR selective agonist (S)-3,5-dihydroxyphenylglycine (DHPG) had the 
opposite effect, increasing the firing activity of PVN neurons in both groups (Li 
et al., 2014).   
Hay et al. (1999) found mild mGluR5 expression in the NTS of Sprague-Dawley 
rats using immunohistochemistry (IHC).  They did not find any expression in the 
CVLM or the RVLM. 
The receptor has also been visualized using IHC in the dorsolateral PAG of 
Sprague-Dawley rats (Azkuea et al.,1997).  In this chapter it was my intention to 
build on the work done by Li et al., Hay et al. and Azkuea et al.   




Given the fact that sympathetic nervous system activity is elevated in SHR and 
that much of the signaling within the sympathetic neuronal networks of the 
brainstem that regulate blood pressure is glutamatergic (see Chapter 1), I also 
sought to compare expression of mGluR5 in the hypertensive SHR vs 
normotensive Wistar rats.  Li et al. already studied expression of the receptor in 
the PVN and NTS but I am also interested in additional regions.  I will not 
exclude the PVN and NTS from my own study, given the fact that Li et al. used 
a different rat strain for their controls and only had an n of 4. 
Using IHC in both normotensive Wistar rats and SHRs, I intended to localize 
mGluR5 in the RVLM, CVLM, NTS, PVN, PAG and the A5 area of the 
ventrolateral pons (See Chapter 1). 
I divided the RVLM and CVLM each into rostral and caudal regions, creating 
four areas of interest in the ventrolateral medulla.  I also examined rostral and 
caudal sections of the NTS.  The specific areas of the PAG that are involved in 
control of blood pressure are the ventrolateral and dorsolateral regions, so I 
examined both of those separately.  My overall aim in this chapter was to map 
and crudely quantify expression of mGluR5 in key CNS nuclei involved in the 
control of blood pressure. 
Methods: 
Tissue Preparation: 
All animal experiments were performed in accordance with institutional 
guidelines and the UK Home Office (Scientific Procedures) Act (1986) with 
project approval from the University of Bristol, University ethics of research 
committee, under Home Office personal license number ICCF4B573 and project 
license number 70/7868.  Six male Wistar and seven male Spontaneously 
 




Hypertensive Rats (SHRs), all approximately 300g, were sourced from Harlan, 
UK.  Wistar rats were used throughout this project instead of the more 
commonly used Wistar-Kyoto (WKY) rat since WKY rats were difficult to 
obtain at the time the research was done and as a result were out of budget.  The 
Wistar rat is closely related to the WKY and therefore the SHR, since SHR were 
obtained by selectively breeding hypertensive WKY rats. Wistars have been used 
as controls in many published studies including those conducted by our group 
(Roloff et al., 2018)  
The animals were overdosed using sodium pentobarbital (150mg/Kg.).  The 
animals were then transcardially perfused using a peristaltic pump, first with 
~200ml phosphate buffered saline - PBS (Dulbecco tablets) and then with 
~200ml 10% buffered formalin (Sakura cat#: 8726).  The animals were 
decapitated via guillotine, the brains were carefully harvested, rinsed and washed 
with PBS and placed into tubes containing 10% formalin for temporary storage 
at 4°C until processing. 
The brains were cut using a razor blade into smaller sections suitable for 







C block: Cerebellum / Brain stem 
B block: Hippocampal 
block 
A block: Striatal block 
Contains NTS, CVLM, RVLM, 
PAG and A5 
Contains PVN, PAG, A5 
Not analysed 
Figure 11:  Schematic showing how brains were cut to fit into blocks to be sectioned on the microtome (ventral view with 
brainstem at top and frontal lobe at bottom). 




The tissue blocks were infiltrated with paraffin wax (Sakura cat# 4502) using a 
Tissue-Tek VIP 6 Vacuum Infiltration Processor (Sakura) according to the 
program shown in Table 1. 
Multiple changes of the same reagent were used to ensure reagents were clean 
and to reduce contamination from the previous type of reagent. 
Solution Concentration (%) Time (mins) Temp (°C) 
Formalin 10 5 Room 
IMS 60 75 Room 
IMS 80 75 Room 
IMS 90 75 Room 
IMS 100 75 Room 
IMS 100 75 Room 
IMS 100 75 Room 
Xylene 100 75 Room 
Xylene 100 75 Room 
Xylene 100 75 Room 
Paraffin wax 100 50 60 
Paraffin wax 100 50 60 
Paraffin wax 100 50 60 
Paraffin wax 100 Until collected 60 
Table 1: Table showing the protocol used to embed tissues in paraffin wax.  IMS=industrial methylated 
spirits 
The tissue was then carefully oriented for sectioning and embedded in wax 
contained within Tissue-Tek III uni casettes (Sakura).   
Once set and cooled to room temperature the tissue blocks were trimmed using a 
sharp knife and cut into 6 μm sections using a manually-operated rotary 




microtome (Thermo).  The sections were floated on water in a bath at ~43°C and 
mounted serially onto glass slides (Thermo cat# 640-ADH-006). The slides were 
labelled and left to dry on a heated drying rack overnight in the order in which 
the sections were cut. 
Slide Selection: 
A series of slides, evenly spaced throughout the series that was cut, was selected 
for solochroming in order to assist with choosing appropriate slides to stain for 
mGluR5. The solochroming process stains myelin deep blue.  This facilitated 
anatomical orientation in conjunction with a brain Atlas (Paxinos & Watson, 
2007).  Solochromed slides that contained cardiovascular control nuclei were 
identified using light microscopy (Leica inverted microscope) and adjacent slides 
from the sequence were selected for mGluR5 staining.  Four slides per region per 
animal were chosen. 
Solochrome staining was performed manually as follows.  Slides were placed by 
hand into racks submerged in reagents at room temperature for specified 
amounts of time and were agitated by hand according to Table 2. 
Multiple changes of the same reagent were used to ensure reagents are clean and 
to reduce contamination from the previous type of reagent. (i.e. when racks are 
moved from xylene into IMS, they take some xylene with them and contaminate 
the IMS, so moving them through 3 batches of IMS for 2 mins each ensures that 
overall the slides spend 6 mins in purer IMS than they would if they were left for 
6 mins in one batch.  If 3 batches of IMS are used, the amount of xylene coming 
through into the third batch is negligible) 
 




Reagent Time (mins) Agitation 
Xylene 2 Initial 
Xylene 2 Frequent 
Xylene 2 Initial 
IMS 2 Initial 
IMS 2 Frequent 
IMS 2 Initial 
70% IMS 2 Frequent 
Running Tap water 5 Frequent 
Solochrome 12 Frequent 
Running Tap water 5 Frequent 
Iron Alum 0.5 Frequent 
Iron Alum 1 Frequent 
Iron Alum 1 Frequent 
Running Tap water 5 Frequent 
Cresyl Violet 3 Frequent 
Running Tap water 1 Frequent 
IMS 70% 1 Continuous 
IMS 1 Continuous 
IMS 1 Frequent 
IMS 2 Frequent 
Xylene 1 Frequent 
Xylene 1.5 Frequent 
Xylene 2 Initial 
Xylene 2 Initial 
Xylene 2 Initial 
Table 2: Table showing the protocol used for solochroming.  IMS=Industrial methylated spirits.  Cresyl 
violet from Sigma (Cat. No. C5042) made into solution according to package instructions. Solochrome and 
iron alum made up according to formulations in Appendix C. 




Xylene and IMS were obtained from Fisher Scientific (cat# X/0250/17 and 
M/4450/17 respectively).  
Once solochroming was complete the slides were cover slipped using an 
automated coverslipping machine (Thermo).  Shandon ClearVue Mountant XYL 
(Thermo cat# 4212) was used as the adhesive to secure the coverslips to the 
slides. 
Staining for mGluR5: 
Selected slides were run through a solvent gradient in order to remove the 
paraffin wax and create an aqueous tissue environment to facilitate 
immunocytochemical staining.  This was done at room temperature in 
accordance with Table 3. 
Multiple changes of the same reagent were used to ensure reagents were clean 
and to reduce contamination from the previous type of reagent. 






70% IMS 5 
Distilled Water 5 
Table 3:  Table showing protocol for rehydrating tissue on slides before staining.  IMS=Industrial 
methylated spirits 
Slides were slotted into racks and placed in a pre-treatment module (Thermo) 
containing 1% citrate buffer (Thermo cat# TA-250-PM1X) at 65°C.  The bath 
was then heated to 100°C over a 20-minute period for antigen retrieval, 




maintained for 20 mins at 100°C before being left to cool to 75°C, which took 
approximately 20 mins.  Antigen retrieval is a process in which methylene 
bridges that are formed between proteins during formalin fixation are broken in 
order to expose antigenic sites that are otherwise blocked by the fixation process.  
The complete cycle took ~1 hr. 
The slides were then removed and placed into distilled water.  A border was 
drawn around the edge of each slide using a PAP pen (thermo), which contains a 
hydrophobic solution in order to prevent solutions running off the slide later on.  
Care was taken to minimise the amount of time the slides were out of the water 
in order to prevent the tissue from drying out.  Slides were then transferred into 
manual staining humidity trays / autostainer machines (Thermo).   
The slides were incubated at room temperature (solutions put onto slides with a 
pipette) in PBS-T (PBS with 0.05% Tween-20 from Thermo) for 5 minutes.  
Tween-20 is a non-ionic surfactant, which helps the solution to spread more 
easily across the slides.  
Next, the solution was tipped/blown (with compressed air) off the slides and 
endogenous peroxidases were blocked via incubation with 0.3% H2O2 (Sigma 
cat# H1009) in PBS-T for 10 mins.  This was followed by a 5-minute rinsing 
step with PBS-T. 
Non-specific binding of the antibody to tissue sites other than the intended ligand 
was blocked via incubation with 5% Normal Goat Serum (Vector Labs cat# S-
1000) in PBS-T for 30 mins.  This was then tipped/blown off the slide and 
without rinsing, the tissue was incubated with primary antibody (Rabbit anti-rat 
mGluR5, Merck Millipore cat# AB5675) at a dilution of 1:5000 in PBS-T for 60 
mins.  This concentration was selected after a series of pilots were performed 




with a wide range of concentrations (1 in 50 to 1 in 500000) as part of antibody 
characterisation/optimisation process using otherwise the same protocol outlined 
here.  After incubation was complete, the slides were rinsed with PBS-T for 5 
mins before a 30 min incubation with the secondary antibody (Biotinylated goat 
anti-rabbit IgG, Vector labs, cat# BA-9200) at a dilution of 1:200 in PBS-T.  A 









After this was washed off with PBS-T for 5 mins, the slides were incubated with 
Avidin-Biotin complex (Vectastain Elite RTU ABC kit, Vector labs, cat# PK-
7100) for 30 mins for further signal amplification.  Another 5 min wash in PBS-
T was done and the signal was developed via a 5 min incubation with 
diaminobenzidine (DAB) (ImmPACT DAB kit, Vector labs, cat# SK-4105) 
made up in the diluent provided according to the kit instructions.  A further 5 
min PBS-T wash took place before counterstaining with a 5 min incubation in 
50% haematoxylin in dH2O (DAKO cat# S3301).  300μL of appropriate solution 
was put onto each slide at every stage. 
Figure 12:  The concept of signal amplification-Using a secondary antibody and 
then an avidin-biotin complex to bind to the primary antibody results in a large 
reporter complex bound to a single epitope, thereby providing a stronger signal 
when the substrate is applied.  Diagram adapted from ThermoFisher 
 




The slides were briefly rinsed with dH2O before being transferred to a warm 
water bath (tap water) at ~45°C.  They were then put through the solvent 
gradient in Table 3 in reverse order.  Once the slides had completed their 5 min 
incubation in the third change of xylene, they were cover slipped as above, left to 
air dry for 20 mins and placed in warm ovens (approx. 45°C) to dry further 
overnight. 
The slides were observed and scanned using an Aperio scanner (Leica) and 
images captured digitally using an Aperio ImageScope software. 
Staining intensity was measured in FiJi software using the ‘staining intensity’ 
tool.  Intensity was measured relative to that of the hippocampus, which was 
deemed 100% as this is a region known to have particularly high expression of 
mGluR5.  For each slide analysed, the darkest area of the hippocampus on each 
image (determined automatically by the software, avoiding user bias) was 
selected and deemed 100% for the purpose of calibration.  The outlines of the 
regions of interest on each slide were selected manually using the freehand shape 
tool, which introduced some potential for both manual error and user bias which 
were unavoidable given the resources available.  The cut-off for detection 
intensity was determined using a section of white matter which does not contain 
any mGluR5 and was deemed zero.  The software was calibrated individually for 
each slide since there was some variation in general staining intensity between 








Validation of Antibody Used: 
The antibody I used to label mGluR5 (Merck Millipore cat# AB5675) has been 
used in numerous studies that have resulted in publication of peer-reviewed 
papers. (Zhong et al., 2012; Grolla et al., 2013; Andreeva et al., 2014; Loweth et 
al., 2014; Haas et al., 2014; Xu et al., 2014). 
In addition, I validated the antibody myself, using the protocol described 
previously but with brain tissue from a genetically-modified animal that did not 
















Figure 13: Section of brain tissue at the level of the PAG treated with anti-mGluR5 
antibody (Merck Millipore cat# AB5675) according to the protocol outlined 
previously. A: Tissue from an mGluR5 knockout animal (no mGluR5 receptor 
present). B: Comparable section from a wild-type animal.  This validation process was 
undertaken in order to show that the antibody used in the experiments was specific 
to mGluR5 and does not bind indiscriminately. 





No significant difference in expression of mGluR5 between SHR and Wistar was 
observed (Figure 14).  Substantial expression of mGluR5 was detected in the 
PVN and rNTS, where staining intensity was more than 60% relative to that of 
the hippocampus.  Moderate expression was observed in the cNTS and dlPAG, 
where staining intensity was between 30 and 40% and mild expression was 
detected in the vlPAG and the A5 area of the ventrolateral pons, where relative 
































Figure 14:  % staining intensity relative to the hippocampus, which was deemed to have 100% intensity.  
Measurements made using ‘staining intensity’ tool in Fiji. Wistars n = 6  SHR n = 7  No significant 
differences were observed between the two strains.  No staining was detected in either the rostral or caudal 
portions of the RVLM or the CVLM in Wistars or SHRs.  Error bars represent SEM. A: Paraventricular 
nucleus of the hypothalamus, B: A5 Area of the ventrolateral pons, C: Dorsolateral periaqueductal grey 
area, D: Ventrolateral periaqueductal grey area, E: Rostral Nucleus of the solitary tract, F: Caudal nucleus 
of the solitary tract 
 
 














    A5 Area of the Ventrolateral Pons  
 
Figure 15: Image of one of my sections taken at the level of the A5 area of the ventrolateral pons, stained 
for mGluR5.  Brown areas indicate presence of the receptor. A: View of the whole section B: Zoomed-in 













Figure 16: Image of one of my sections at the level of the rostral NTS, stained for mGluR5.  Brown areas 
indicate presence of the receptor. A: View of the whole section B: Zoomed-in view of the area of interest, 
rostral NTS circled in blue. Green circle in panel A indicates RVLM.  No staining was detected in the RVLM. 
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CVLM (green circle) + Caudal NTS (red square) 
A 
B 
Figure 17: Image of one of my sections at the level of the caudal NTS, stained for mGluR5.  Brown areas 
indicate presence of the receptor. A: View of the whole section B: Zoomed-in view of the area of interest, 
caudal NTS outlined in blue. Green circle in panel A indicates CVLM.  No staining was detected in the 
CVLM. 
1mm 















Periaqueductal Grey Area 
A 
B 
Figure 18: Image of one of my sections at the level of the periaqueductal grey area, stained for mGluR5.  
Brown areas indicate presence of the receptor. A: View of the whole section B: Zoomed-in view of the 
area of interest, periaqueductal grey area outlined in blue. 
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Figure 19: Image of one of my sections at the level of the PVN, stained for mGluR5.  Brown areas indicate 
presence of the receptor. A: View of the whole section B: Zoomed-in view of the area of interest, PVN 
outlined in blue. 
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mGluR5 is Expressed in Several Key Nuclei Involved in Autonomic 
Regulation of Blood Pressure: 
NTS: 
Substantial expression of mGluR5 was detected in the NTS (Figure 14 panels E 
and F).  The NTS is a major integrator of cardiovascular afferent information 
(see Chapter 1). 
Expression in the NTS was higher in the rostral portion of the nucleus.  The NTS 
does not have a laminar structure separating second order interneurons receiving 
afferent sensory information from neurones that project to other areas in the 
brainstem.  However, there is some viscerotopic organization of the nucleus; the 
rostral portion primarily receives sensory afferents conveying gustatory and 
other orosensory information (Subramanian, 1995; Norgren, 2011) via cranial 
nerves V, VII, IX and the Vagus (Beckstead & Norgren, 1979; Nomura & 
Mizuno, 1981; Contreras et al., 1982; Bradley et al., 1985; Hanamori & Smith, 
1989).  The cardiorespiratory afferents synapse with NTS interneurons in the 
caudal portion of the nucleus (Altschuler et al., 1989; Ciriello et al., 1994).  
Detection of mGluR5 here is particularly pertinent to this thesis as this caudal 
subregion of the NTS is heavily involved in blood pressure control.  There does 
not appear to be any viscerotopic organization of efferent neurons responsible for 
cardiorespiratory control.  However, neurons in the NTS have many long 
dendrites (Standish et al., 1995) and it may be the case that afferents synapse 
onto these dendrites rather than the somas.  Because of this, all of the NTS 
potentially contains neurones or dendrites that could project to, and modulate, 
neural circuits controlling sympathetic outflow; therefore, detection of mGluR5 




in any part of the NTS is important – a systemically administered compound 
modulating mGluR5 has the potential to modulate sympathetic outflow at the 
level of the NTS and thereby affect blood pressure.   
PVN: 
Strong expression of mGluR5 was detected in the PVN (Figure 14, panel A).   
This is highly significant since this nucleus contains parvocellular neurones that 
innervate the RVLM (home of the pre-motor sympathetic neurones) and to the 
intermediolateral cell column where the pre-ganglionic sympathetic motor 
neurons are located. The PVN magnocellular neurons control vasopressin 
secretion into the blood stream and the nucleus also has projections to other 
regions involved in blood pressure control (see Chapter 1). 
As is the case in the NTS, the presence of mGluR5 in this nucleus provides the 
potential for altering blood pressure since the PVN constitutes a critical 
component of the neuronal circuitry controlling sympathetic outflow.  
Expression of the receptor in this particular nucleus is especially pertinent to my 
research since the PVN is a cardiorespiratory control region that is vulnerable to 
dysfunction caused by immune cell infiltration due to its proximity to the CVOs, 
which have an incomplete BBB that is compromised in hypertension (see 
Chapter 1).  It is possible that immune cell infiltration causes abnormal neuronal 
activity within the PVN, which leads to abnormal activity downstream and 
ultimately increased sympathetic outflow.  If this is the case, modulation of 
mGluR5 could potentially correct the overstimulation of neurons in the PVN and 
thereby normalize sympathetic outflow to the cardiovascular effector organs, 
reducing blood pressure. 
 





Some expression of mGluR5 was detected in the vlPAG and dlPAG (Figure 14, 
panels C and D), although the staining intensity was considerably lower than it 
was in the NTS and PVN.  Regardless, the presence of the receptor in these 
regions provides the potential for blood pressure modulation via mGluR5 since 
they are known to contain neurones which project to the RVLM and the 
hypothalamic PVN as discussed in Chapter 1. 
A5: 
mGluR5 was detected in the A5 area but this finding is not especially helpful 
since the A5 noradrenergic neurones of interest within this region are disperse 
(see Chapter 1). Because of this, it is possible that the staining observed was due 
to expression on neurones that are not involved in cardiovascular homeostasis 
and that the neurones of interest do not express the receptor. 
CVLM and RVLM: 
No expression of mGluR5 was detected in the CVLM or the RVLM.  This is 
surprising since the majority of the signaling to the caudal ventral lateral medulla 
is known to be glutamatergic but mediated by non-NMDA receptors (see 
Chapter 1).  There is some pharmacological evidence that mGluR5 is expressed 
in the RVLM (Urban et al., 2003).  Perhaps the concentration of receptor at this 
region was below what would be picked up by my analysis. 
No Significant Difference in mGluR5 Expression between SHRs and 
Normotensive Wistar Controls: 
According to my data, mGluR5 density as measured compared to the density in 
the hippocampus does not appear to be upregulated in the SHR.  However, Li 




and Pan found that expression of the receptor was increased in SHR (Li et al., 
2014).  Li and Pan used Western blotting and qPCR to measure the quantity of 
protein extracted from the nuclei, which is a much more accurate method than 
IHC for quantification and therefore their data is likely more reliable.  Li and Pan 
used WKY rats as controls which could possibly explains the discrepancy 
although this is unlikely since WKY rats and Wistars are closely related.  Even if 
there is no difference in the levels of expression of mGluR5 between Wistar and 
SHR, this does not necessarily mean that signaling via these receptors is not 
altered in the hypertensive SHR.  It is possible that more glutamate is released at 
the synapses of SHR or that reuptake of glutamate from the synaptic cleft is 
reduce and thereby there is more excitatory signaling along autonomic pathways 
despite there being no appreciable increase in receptors. It is also possible that 
the signaling pathway in SHR is more responsive or that an additional pathway is 
recruited downstream of mGluR5. 
Limitations and Further Study: 
As alluded to above, IHC is not the best method for accurate quantification of 
protein expression within a tissue.  If I needed to quantify the expression of 
mGluR5 I could have used Western blotting or measured mRNA using qPCR. 
However, the primary purpose of this study was not to accurately quantify 
mGluR5 expression but to screen various key cardiovascular control nuclei for 
the presence of the receptor in order to determine whether this receptor could 
constitute a potential target for modulation of blood pressure.  The study 
achieved this aim. Indeed, it has unearthed a number of potential nuclei 
including the NTS, PAG and PVN.  




Ideally I would like to have expanded the study by performing 
immunofluorescence staining and co-staining for tyrosine hydroxylase in order 
to determine whether the catecholamine containing neurones (A1, A2, A5, C1 – 
see Chapter 1) co-express mGluR5 in particular since my blanket IHC stain of 
the A5 area of the ventrolateral pons does not provide information regarding 
expression of mGluR5 in neurons that are known to be involved in the control of 
blood pressure.  Unfortunately, my placement at Lilly was not long enough to 
allow for this.  Overall this study did provide evidence of the presence of 
mGluR5 in several key nuclei responsible for blood pressure control and justifies 













Chapter 3:  In Vivo Pharmacological Modulation of 
mGluR5 
Introduction: 
Systemic administration of a positive allosteric modulator of mGluR5 has caused 
increases in blood pressure in ferrets, as discussed in Chapter 1. 
Li and Pan administered compounds that modulate mGluR5 into the PVN 
specifically in 2010 (see Chapter 1).  They bilaterally injected LY367385 or 
MPEP, specific mGluR1 and mGluR5 antagonists respectively, into the PVN of 
SHR and WKY rats.  They observed reductions in both sympathetic nerve 
activity and blood pressure in SHR but not in WKY rats, suggesting that group 1 
mGluRs are present in the PVN and that they are involved in producing or 
contributing to the hypertension, probably via increasing sympathetic outflow.  
The effects elicited by MPEP were significantly greater than those by 
LY367385, suggesting a particularly significant role for mGluR5 (Li and Pan, 
2010).  They also observed increases in sympathetic nerve activity and blood 
pressure of SHR and WKY rats when they injected DHPG into the PVN.  DHPG 
is a non-specific agonist of both group 1 mGluRs.  These effects were 
significantly attenuated when DHPG was co-administered with MPEP and were 
abolished when it was co-administered with both MPEP and LY367385, 
reinforcing the findings from the antagonist experiments. Given the fact that Eli 
Lilly and company used ferrets for their systemic study and there is no ferret 
model of congenital hypertension as well as the fact that partly due to their 
greater similarity to humans, rats are the standard animal used for research into 
hypertension, I intended to investigate the effects of modulation of mGluR5 in 
the SHR (see Chapter 1) and normotensive Wistar rats.  Also, the ferret study 




from Lilly and the microinjection study from Li and Pan were both acute studies.  
I intended to observe the effects of chronic modulation of the receptor using 
twice daily intraperitoneal injections.  I used the same positive allosteric 
modulator used by Lilly (LSN2814617) in normotensive rats, since it is known 
to produce a hypertensive response in normotensive ferrets.  The response 
observed at 3mg/Kg was only a little less pronounced than at much larger doses, 
so I used 3mg/Kg as the top end of my dosing range.  The main focus of these 
experiments was testing mGluR5 antagonists on SHR since it is possible that 
such compounds could be of some therapeutic use if they prove to be anti-
hypertensive.  The most widely used mGluR5 antagonist is 2-Methyl-6-
(phenylethynyl) pyridine (MPEP) and for this reason I used the compound in my 
study.  However, because MPEP is known to have some activity as a positive 
allosteric modulator of mGluR4 (Mathiesen et al., 2003) and is less potent than 
the more recently developed 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP), 
which has no known activity at any receptor other than mGluR5, I tested MTEP 
as well. 
In order to help determine the appropriate dosing schedule I did a small 
pharmacokinetic study.  I injected 8 male Wistar rats with MPEP (8mg/Kg) and 
another 8 with MTEP (4mg/Kg).  I then withdrew blood via tail vein bleed into 
Eppendorf tubes (see Methods section of this chapter) and span the cells down in 
a mini centrifuge (Eppendorf) in order to isolate the plasma, which I collected, 
froze at -80°C and sent to Eil Lilly and Company (Windlesham, Surrey, UK) for 
HPLC analysis (Figure 20 and Figure 21). 
                                                                
                                     




                   
Figure 20:  Pharmacokinetic study on MPEP.  8 male Wistar rats were given an I.P. injection of 8mg/Kg MPEP at 
T=0.  Blood was withdrawn via tail vein bleed at the three time points (1.5, 4.5 and 7.5 hours) and the plasma 
concentration was measured via HPLC by staff at Eli Lily and Company. Error bars show SEM. 
Figure 21:  Pharmacokinetic study on MTEP.  8 male Wistar rats were given an I.P. injection of 4mg/Kg MTEP at 
T=0.  Blood was withdrawn via tail vein bleed at the three time points (1.5, 4.5 and 7.5 hours) and the plasma 































































Based on this data I decided that it would be necessary to inject the animals twice 
per day, once in the morning and once in the evening.  Ideally, the animals would 
have been given three injections equally spaced throughout each day, but this was 
not practical.    
Many groups use the tail cuff method to measure blood pressure in animals 
(Kubota et al., 2006).  This is not ideal because it gives artificially high readings 
due to the animals experiencing handling stress and also because data has to be 
collected manually and the number of data points is thereby limited to what is 
practically possible.  I used radio-telemetry.  This is a technique in which blood 
pressure and heart rate are measured by a small device that is implanted inside 
the abdominal cavity of the animal and the data is relayed to acquisition software 
on a connected computer (see methods section of this chapter).  This system is 
superior to the tail cuff method since data is acquired continuously whilst the 
animal is undisturbed in its home cage, leading to more accurate measurement 
and substantially reducing the incidence of anomalous results. 
Methods: 
Experiment Design: 
All animal experiments were performed in accordance with institutional 
guidelines and the UK Home Office (Scientific Procedures) Act (1986) with 
project approval from the University of Bristol, University ethics of research 
committee, under Home Office personal license number ICCF4B573 and project 
license number 70/7868. 
Blood pressure and heart rate data were collected via radio-telemetry:  A setup in 
which a device implanted in the abdomen of each animal receives BP and HR 
information via a catheter inserted into the descending aorta and transmits it to a 




receiver platform beneath the animal’s home cage.  This allows chronic 
measurement of HR and BP without disturbing the animal, which avoids the 
artificially high/variable readings obtained by the tail-cuff method. 
Animals were given unlimited access to water and standard chow throughout the 
study. 
Each experiment was divided into four phases:  Baseline, Vehicle, Treatment and 
Washout.  During the baseline phase, the animals were left undisturbed for one 
week.  In the vehicle phase, the animals were given intraperitoneal injections of 
1ml vehicle twice daily for one week.  In the treatment phase, the animals were 
given intraperitoneal injections of 1ml appropriate drug solution twice daily for 
one week. The immediate 30 mins of recorded data succeeding injections was 
excluded in order to account for handling stress.  In the washout phase the 
animals were once again left undisturbed for 1 week. 
Data was collected and analysed using Spike2 (CED). 
Implantation of Radio-Telemetry Device: 
Male Wistar rats or male SHRs at ~300g were sourced from Harlan, UK.  The 
animals were anaesthetised via intra-muscular injection of ketamine (60 mg kg-1) 
and medetomidine (250 mg kg-1).  The depth of anaesthesia was assessed by the 
presence or absence of the pedal withdrawal reflex when the animal was 
subjected to noxious pinching of the foot.   Once anaesthetised, the animal was 
placed on its back and its abdomen was shaved using electric clippers (Wahl).   
The animal was placed on a heated pad and a surgical drape was placed over it 
with the shaved abdomen area exposed.  This area was cleaned with Hydrex Pink 
Surgical Scrub and a midline incision of the abdominal wall was made using a 
scalpel.  The intestines were moved aside to reveal the abdominal aorta and a 




sterile gauze horseshoe, moistened with sterile saline, was inserted into the 
abdominal cavity in such a way as to hold the intestines out of sight and maintain 
good vision of the aorta.  Stainless steel retractors were used to assist with this. 
Under a dissecting microscope (Leica), a ligation aid (FST cat #18062-12) was 
used to separate the aorta and the vena cava below the renal bifurcation and 
above the femoral bifurcation.  Ligation sutures (FST) were placed at both 
locations.  These were pulled tight, using haemostats to weight them down and a 
small vascular clip (FST cat# 18055-04) was applied above the top ligation 
suture in order to occlude blood flow.  A 21G needle (BD microlance 3) was 
used to make an incision in the lower portion of the aorta into which the catheter 
of the transmitter (DSI TA11PA-C40) was inserted, caudal to the root of the left 
renal artery.  A small amount of tissue adhesive (Vetbond) was applied to the 
catheter-insertion site and a small cellulose patch (Fisher cat# NC9590679) was 
glued over it.   
The small vascular clip was then removed and the ligation sutures loosened.  In 
the event that bleeding occurred, these were briefly tightened again and more 
tissue adhesive was applied as necessary.  Finally, the sutures, gauze horseshoe 
and retractor were removed, the intestines put back in place and the surgical 
wound was closed using single interrupted sutures and fixing the transmitter to 
the inside of the abdominal wall in the process.   
The anaesthesia was reversed with a subcutaneous injection of atipamezole (1 
mg kg-1) and ~2ml of Hartman’s solution was injected subcutaneously for the 
purpose of rehydration.   The animal was then returned to its home cage for 
recovery.  Subcutaneous injections of meloxicam (1 mg kg-1) were used for pain 
management.  Usually only one injection was given (on the day of the surgery) 




but in some cases additional injections were given after seeking advice from the 
named veterinary surgeon when an animal appeared to be in pain one or two 
days post-surgery. 
Drug Solutions and Injection Procedure: 
LSN2814617: 
This drug did not dissolve in saline.  The following vehicle was advised by the 
manufacturer (Eli Lilly): 
1% Hydroxyethylcellulose (sigma); 0.25% Polysorbate 80 (sigma); 0.05% 
Antifoam (DowCorning RD emulsion) v/v in sterile saline.  This vehicle did not 
completely dissolve the drug.  Sonication was required.  The drug suspension 
was put into a 50ml Falcon tube on ice and was sonicated at 45% amplitude with 
a Sonics Vibracell probe sonicator for 30 mins.  This produced a very fine 
suspension suitable for intraperitoneal injections.  A clear solution could not be 
achieved. 
MPEP and MTEP: 
Both of the antagonists dissolved easily in sterile saline at room temperature with 
mild mixing. 
Injections: 
On injection days animals were taken one by one in their home cages to a 
procedure room, placed into a thin, transparent restraint tube (Decapicones, 
Braintree Scientific) and given intraperitoneal injections of vehicle or 
appropriate drug treatment (prepared as described above) before being returned 
to their home cages.  No other drugs (sedatives etc.) were given.  The two 
injections were given 8-12 hours apart on each injection day. 





Twice-daily IP injections of 0.3mg/Kg LSN2814617 into normotensive male 
Wistar rats produced a significant increase in BP (p=0.032) and heart rate 
(p=0.041) on the first day only.  Increasing the dose of LSN2814617 to 1mg/Kg 
produced a significant (p=0.039) increase in BP of a greater magnitude than at 
the lower dose.  The HR at this dose also trended upwards, although the increase 
was not statistically significant.  The maximum dose of 3mg/Kg LSN2814617 
produced a significant (P=0.029) increase in BP that was greater still than that 
obtained with 1mg/Kg and a similar upwards but non-significant trend was 
observed in the HR.  Increasing the dose did not produce significant effects on 
days beyond day 1, in every case the BP and HR trended back towards baseline 
after day 1. 
No significant effects were produced by twice daily IP injection with MPEP into 
male SHRs at 1,3 or 9mg/Kg.  However, MTEP produced a significant (p=0.044) 
decrease in BP on day 1 at 1mg/Kg and a slightly larger significant (p=0.038) 
decrease on day 1 at 6mg/Kg.  No significant effects on HR were observed and 




































































Baseline Vehicle Drug Washout
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* 
Figure 22:  Effect of twice daily intraperitoneal injections of 0.3mg/Kg LSN2814617 on blood pressure (Panel A) and heart rate (Panel B) on 
300g normotensive male Wistar rats. Animals were left untreated for an initial 7 days (baseline period), given vehicle only for the next 6 days, 
given LSN2814617 for the next 7 days and then left untreated for the final 6 days (washout period). Each datapoint shows mean of readings 
taken every 10 mins throughout each day. 30 minutes of data excluded after each injection in order to minimise impact of handling stress. 


































































Baseline Vehicle Drug Washout 
Baseline Vehicle Drug Washout 
Figure 23:  Effect of twice daily intraperitoneal injections of 1mg/Kg LSN2814617 on blood pressure (Panel A) and heart rate (Panel B) on 300g 
normotensive male Wistar rats. Animals were left untreated for an initial 7 days (baseline period), given vehicle only for the next 7 days, given 
LSN2814617 for the next 7 days and then left untreated for the final 1 day (washout period was cut short by a power cut, which stopped recording 
of data). Each datapoint shows mean of readings taken every 10 mins throughout each day. 30 minutes of data excluded after each injection in 
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3mg/Kg LSN2814617 Twice Daily IP       
* 
Figure 24:  Effect of twice daily intraperitoneal injections of 3mg/Kg LSN2814617 on blood pressure (Panel A) and heart rate (Panel B) on 300g 
normotensive male Wistar rats. Animals were left untreated for an initial 7 days (baseline period), given vehicle only for the next 7 days, given 
LSN2814617 for the next 7 days and then left untreated for the final 7 days (washout period). Each datapoint shows mean of readings taken every 








































































Figure 25:  Effect of twice daily intraperitoneal injections of 1mg/Kg MPEP on blood pressure (Panel A) and heart rate (Panel B) on 300g 
hypertensive male SHR rats. Animals were left untreated for an initial 7 days (baseline period), given vehicle only for the next 7 days, given 
MPEP for the next 7 days and then left untreated for the final 7 days (washout period). Each datapoint shows mean of readings taken 
every 10 mins throughout each day. 30 minutes of data excluded after each injection in order to minimise impact of handling stress. Error 
bars show SEM. n=8 
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Figure 26:  Effect of twice daily intraperitoneal injections of 3mg/Kg MPEP on blood pressure (Panel A) and heart rate (Panel B) on 300g 
hypertensive male SHR rats. Animals were left untreated for an initial 7 days (baseline period), given vehicle only for the next 7 days, given 
MPEP for the next 7 days and then left untreated for the final 7 days (washout period). Each datapoint shows mean of readings taken every 10 
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Figure 27:  Effect of twice daily intraperitoneal injections of 3mg/Kg MPEP on blood pressure (Panel A) and heart rate (Panel B) on 300g 
hypertensive male SHR rats. Animals were left untreated for an initial 7 days (baseline period), given vehicle only for the next 7 days, given 
MPEP for the next 7 days and then left untreated for the final 7 days (washout period). Each datapoint shows mean of readings taken 
every 10 mins throughout each day. 30 minutes of data excluded after each injection in order to minimise impact of handling stress. Error 
bars show SEM. n=6 
 


































0 5 10 15 20 25 30 35
Change in MNHR
1mg/Kg MTEP Twice Daily IP       
* 
Baseline Vehicle Drug Washout 
Baseline Vehicle Drug Washout 
A  
B  
Figure 28:  Effect of twice daily intraperitoneal injections of 1mg/Kg MTEP on blood pressure (Panel A) and heart rate (Panel B) on 300g 
hypertensive male SHR rats. Animals were left untreated for an initial 7 days (baseline period), given vehicle only for the next 7 days, given 
MPEP for the next 7 days and then left untreated for the final 7 days (washout period). Each datapoint shows mean of readings taken every 10 
mins throughout each day. 30 minutes of data excluded after each injection in order to minimise impact of handling stress. Error bars show 
SEM. n=6 
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Figure 29:  Effect of twice daily intraperitoneal injections of 3mg/Kg MTEP on blood pressure (Panel A) and heart rate (Panel B) 
on 300g hypertensive male SHR rats. Animals were left untreated for an initial 7 days (baseline period), given vehicle only for the 
next 7 days, given MPEP for the next 7 days and then left untreated for the final 7 days (washout period). Each datapoint shows 
mean of readings taken every 10 mins throughout each day. 30 minutes of data excluded after each injection in order to 
minimise impact of handling stress. Error bars show SEM. n=6 
 





Positive Allosteric Modulation of mGluR5 Via Twice Daily Injections of 
LSN2814617 Increases Blood Pressure and Heart Rate on a Temporary 
Basis: 
Twice daily intraperitoneal administration of LSN2814617 significantly raised 
blood pressure in normotensive Wistar rats (Figures 22, 23 and 24).  However, 
the effect appears to be transient such that within 2-3 days pressures return to 
normal after that period.  This increase did not occur after injections of vehicle 
controls so non-pharmacological factors such as stress can be ruled out.  The fact 
that the compound raised blood pressure initially was not surprising, given the 
preliminary data provided by Eli Lilly and Company (Figure 10) although their 
data came from experiments in ferrets and the effect may not have occurred in 
rats.  Their use of a different animal may also explain the fact that the pressure 
increase they observed was significantly larger than what I observed in rats, 
reflecting a possible species difference.  Interestingly, the tolerance appears to 
have manifested more quickly at higher doses. 
There are multiple mechanisms that could explain the tolerance to the 
compound.  Firstly, it is possible that the blood pressure response returns to 
baseline after 2-3 days due to pharmacokinetic tolerance; time-dependent 
changes in the distribution or metabolism of the drug may be resulting in a lower 
concentration of pharmacologically active compound at the site of mGluR5 
receptors in the nuclei of interest.  Tolerance occurring via this mechanism is 
known to affect many compounds targeting receptors in the CNS, for example 
phenytoin, phenobarbital and carbamazepine (Nijhawan et al., 1990; Hussein et 
al., 2013).  These anti-epileptic drugs cause an increase in hepatic enzymes 




which result in a faster rate of metabolism (Nijhawan et al., 1990; Hussein et al., 
2013).  Because of the increase in the rate of metabolism of the drug, higher 
subsequent doses must be given in order to maintain desired serum 
concentrations.   
The distribution of the PAM could be affected by induction of drug-efflux 
transporters such as p-glycoprotein or proteins belonging to the multi-drug 
resistance family (MRPs), which are expressed on a variety of cell membranes 
including endothelial cells comprising the BBB (Schinkel & Jonker, 2003).  An 
increase in expression of these proteins in response to the PAM could result in 
less drug reaching the CNS (Löscher & Potschka, 2005). Additionally, induction 
of MRPs in the proximal tubule of the kidney or the canalicular membranes of 
hepatocytes could promote increased excretion of the PAM via the urine and 
bile. 
Another possibility is that the animals are exhibiting pharmacodynamic 
tolerance; the PAM is eliciting a response within the target neuronal network 
which reduces the effect of the drug when it is administered again.  Synaptic 
activity is known to induce Homer1a (Brakeman et al., 1997; Vazdarjanova et 
al., 2002), which uncouples mGluR5 from its postsynaptic effectors (Xiao et al., 
2000; Kammermeier & Worley, 2007).  It is possible that increased activity of 
mGluR5 as a result of the PAM initially results in increased neuronal excitability 
and thereby activity, which induces Homer1a, resulting in uncoupling of the 
receptor from its downstream effectors, restoring neuronal activity to baseline. 
In addition, the responsiveness of GPCRs is modulated at the level of the G-
protein by proteins known as regulators of G-protein signalling (RGS), which 
promote guanosine triphosphate hydrolysis by the alpha subunit of G-proteins, 




which feeds back and terminates GPCR signalling pathways (De Vries et al., 
2000). 
Alternatively, or perhaps additionally, interaction between the PAM and the 
receptor or the increase in neuronal signalling resulting from said interaction 
may induce endocytosis of the receptor or down-regulation of receptor 
expression.   
Over-stimulation of GPCRs (both acute and chronic) is known to be protected 
against by a process of receptor internalisation in response to agonists.  In the 
case of persistent stimulation, when agonist binds to a receptor, G-protein 
coupled receptor kinases (GRKs) bind the receptor-agonist complex, resulting in 
phosphorylation of the receptor (Krupnick & Benovic, 1998; Ferguson, 2001).  
Arrestins then also bind to the cytoplasmic face of the receptor, preventing G-
protein interaction.  The binding of Arrestins facilitates receptor endocytosis via 
the clathrin-coated pit pathway (Moore et al., 2007).   This process is outlined in 
Figure 30. 





Figure 30:  Schematic adapted from Moore et al., 2007 outlining endocytosis of GPCRs via the clathrin-
coated pit pathway. GTP = GTP binding protein, GRK GRK = G-protein coupled receptor kinase, PIP2 = 
Phosphatidylinositol 4,5-bisphosphate, PIP3 = Phosphatidylinositol (3,4,5)-trisphosphate, AP2 = AP2 
adaptor complex. 
 
Fourgeaud et al. showed that mGluR5 can be endocytosed by a clathrin-
independent pathway (Fourgeaud et al., 2003).  It was later discovered that this 
occurs via the Caveolar/Lipid Raft Pathway (Francesconi et al., 2009).  Caveolae 
are cone-shaped invaginations of the plasma memberane (Anderson, 1993; 
Razani et al., 2002).  Caveolins, structural proteins, are essential for the integrity 
of caveolae (Cameron et al., 1997).  In this regard, caveolins serve a similar 
function to clathrin in clathrin-coated pits.  Neurones do not possess caveolae but 
caveolin proteins are expressed in these cells and other cells lacking caveolae, 
such as leukocytes (Head & Insel, 2007).  Caveolins serve a purpose as 
scaffolding proteins in these cells and may be involved in signal transduction 
(Head and Insel, 2007).  More research on the involvement of caveolins in 
mGluR5 internalisation specifically is required.  




The degree to which an agonist induces receptor endocytosis varies depending 
on the ligand; a single dose of cocaine causes a significant reduction in surface 
expression of mGluR5 (Fourgeaud et al., 2004). 
Finally, it is possible that mGluR5 does not have a significant influence on 
neural circuitry that is involved in long-term blood pressure control.  If 
modulation of the receptor does not change the blood pressure ‘set-point’ then 
homeostatic mechanisms (outside of the circuity that mGluR5 does influence) 
will return the pressure to the set-point and the altered mGluR5 signalling will be 
dealt with in the same manner as any other hyper/hypotensive stimulus by, for 
example, blood volume modification. 
In addition to increasing blood pressure, the PAM caused a significant increase 
in heart rate that persisted for the same period as the pressor response.  An 
increase in blood pressure coupled with an increase in heart rate was not 
expected since a blood pressure increase should induce a baroreceptor reflex 
reduction in heart rate mediated via activation of the vagus and inhibition of 
sympathetic activity.  The fact that both blood pressure and heart rate increased 
simultaneously could suggest that the PAM is depressing the baroreflex, thereby 
allowing both blood pressure and heart rate to rise.  This effect would most likely 
occur due to modulation of signalling in the PVN, since stimulation of neurones 
in this region is sympathoexcitatory due to the inhibitory effects this has on the 
baroreflex signalling in the NTS (Figure 2).  This fits with data from Li and Pan 
(2010), who found that agonism of mGluR5 in the PVN raised blood pressure, 
heart rate and SNA.  Alternatively, or additionally, my observations may be due 
in part to mGluR5 activity in the periphery.  The receptor is present in the heart 
itself and perhaps LSN2814617 elicits effects by acting directly on the organ to 




increase the rate of contraction and blood pressure (Gill et al., 1999; Xie et al., 
2015). 
Twice-Daily Intraperitoneal Injections of MPEP has no significant effect on 
Blood Pressure in SHRs: 
Twice-Daily Injections of MPEP in SHRs did not produce the reduction in blood 
pressure that was expected (Figures 25, 26 and 27).  This could be explained by 
the fact that MPEP has off-target effects at NMDA receptors (O’Leary et al., 
2000; Movsesyan et al., 2001) and mGluR4 (Mathiesen et al., 2003).  It is also 
possible that the dose used was too low.  Although a wide-range of literature was 
consulted for dose-selection purposes, most studies using MPEP are conducted 
in order to study psychological conditions such as addiction and observable 
effects in this field may manifest at low doses, sub-threshold to a blood pressure 
response.  Financial considerations also had to be made - doses as high as 
50mg/Kg as used in some studies, would not have been possible here. 
mGluR5 Antagonism via Twice-Daily Intraperitoneal Injections of MTEP 
Reduces Blood Pressure in SHRs on a Temporary Basis: 
Twice-daily injections of MTEP did produce a reduction in blood pressure.  The 
magnitude of the effect was similar to what was observed with the PAM.  This 
was expected based on the preliminary data from Lilly and my own data showing 
the blood pressure rising in response to the PAM. It also fits with data from Li 
and Pan (2010), who found that antagonism of mGluR5 in the PVN reduced 
blood pressure.  However, Li and Pan also found that the heart rate was reduced 
along with blood pressure, which I did not find – I found no significant 
differences in heart rate after treatment with MTEP but the heart rate data was 
erratic and was trending in opposite directions for each of the doses before the 




drug was even administered (Figures 28 and 29).  I am not confident that my 
heart rate data is reliable in this study due to the instability observed in the 
vehicle phase. 
Precious little research into the involvement of mGluR5 in blood pressure 
control has been conducted.  Taking the findings of Li and Pan into account with 
my own and the fact that Holbein et al., found that activation of mGluRs in the 
PVN is sympathoexcitatory (Holbein et al., 2012), I would conclude that 
modulation of mGluR5 affects blood pressure control at the level of the 
sympathoexcitatory neurones of the PVN but add in the caveat that we do not 
have evidence to rule out direct involvement of other key nuclei or indeed 
activity of mGluR5 in the periphery.  It is unlikely that systemic mGluR5 
antagonism will ever be used as a treatment for hypertension due to the 
likelihood of off-target affects manifesting as a result of modulation of a receptor 
that is widely expressed, especially in the cortex. 
Limitations and Future Studies: 
As discussed, the fact that the drug was administered systemically in this study 
makes it impossible to determine with any certainty the specific mechanism for 
mGluR5 modulation.  Initially I planned to administer the compounds via ICV 
infusion but the solubility of LSN2814617 in any physiological vehicle was 
extremely poor, so this was not possible; even using a vehicle specifically 
recommended by the manufacturer and with extensive sonication the end result 
was a very fine suspension rather than a solution.  This was appropriate for 
intraperitoneal injection but was not appropriate for use in osmotic minipumps, 
which would have been the preferred delivery method.   




The fact that the animals were injected twice daily may have caused them to be 
stressed – adding in a confounding variable that would have been eliminated if it 
was possible to use a continuous, automatic drug delivery system such as the 
osmotic minipumps.  This stress due to repeated handling and injection may 
explain the large standard errors observed with heart rate data even during the 
vehicle phase. 
Even with continuous, hands-off drug delivery, the fact that the PAM and both 
antagonists cross the BBB would not resolve the issue of being unable to locate 
the exact nucleus mediating the observed effects on blood pressure.  Instead, 
additional studies need to follow the lead of Li and Pan, microinjecting 
compounds modulating mGluR5 into the various nuclei responsible for blood 
pressure control.  In this way the involvement of each nucleus could be tested on 
an individual basis.  It would also be useful to administer the drugs 
intracerebroventricularly whilst also systemically administering compounds with 
the ‘opposite’ effect that are restricted to the periphery.  E.g. Give MTEP 
centrally and an mGluR5 agonist that cannot cross the BBB via an IV or IP 
injection.  Assuming the agonist and antagonist effects of the compounds would 
effectively cancel each other out in the periphery, the antagonist (MPEP) acting 
alone in the CNS would allow for confirmation of the hypothesis that the effects 
on blood pressure I have observed were indeed due to activity on central blood 
pressure control neuronal circuitry rather than on peripheral targets.  
Unfortunately drugs suitable for such a study do not currently exist. 
In order to gain a mechanistic understanding of the effects I observed, I would 
have liked to do spectral analysis of heart rate variability (Karemaker, 1997).  
This would allow me an insight into balance between the sympathetic and 




parasympathetic components of autonomic outflow.  Unfortunately, I did not 
have time to do this.  Ideally, I would have been able to actually measure SNA 
but this was not possible.   
It would have been interesting to conduct an experiment in which I followed the 
compounds modulating mGluR5 with administration of hexamethonium.  
Hexamethonium blocks the nicotinic acetylcholine receptors utilised by the 
sympathetic system and the parasympathetic ganglia.  Because of this, 
hexamethonium causes a large decrease in blood pressure by eliminating 
autonomic outflow.  Although hexamethonium blocks both sympathetic and 
parasympathetic activity, this experiment would allow an indirect measurement 
of any changes caused by mGluR5 modulation in sympathetic drive controlling 
vasomotor tone specifically, since in the case that LSN2814617 increases 
vasomotor tone and MTEP reduces it, a larger drop in blood pressure would be 
observed with the PAM compared to MTEP upon administration of 
hexamethonium and the resultant loss of vasomotor tone, which is maintained 













Chapter 4:  Assessment of T-Cell Phenotype in 
Normotensive Vs. Hypertensive Humans 
 
Introduction: 
Cluster of Differentiation: 
Leukocytes express a multitude of cell surface proteins that can be used 
for immunophenotyping since the combination of proteins expressed by a 
cell depends on the type of cell, the function of the cell and the condition 
the cell is in (e.g. antigen experienced vs. naïve cells).  These proteins are 
functional and include receptors, ligands for receptors on other cells or 
adhesion molecules involved in activities such as leukocyte recruitment 
to sites of inflammation.   A protocol known as Cluster of Differentiation 
(CD) has been developed in order to identify these proteins.  The proteins 
are given a numerical CD designation at Human Leukocyte 
Differentiation Antigens (HLDA) workshop conferences 
(http://www.hcdm.org/) which are held around the world periodically.  
These CD numbers are then used as standard nomenclature by the 
scientific community. 
Fluorescence-Activated Cell Sorting (FACS) – A Method to 
Phenotype Cells: 
A common technique for identifying CD markers is Fluorescence-
Activated Cell Sorting (FACS), which is a specialised form of flow 
cytometry.  Basic flow cytometry uses lasers to identify cells based on 
their light-scattering properties.  A cell suspension is fed into the machine 




and through a nozzle, the cells are arranged into a single file.  The cells 
are passed in front of a laser and light scattered from the cells is detected 
by an electronic sensor array.  One detector directly in front of the laser 
detects forward scatter (FSC) and others to the side detect side scatter 
(SSC).  FSC is correlated with the size of the cell and SSC with the 
granularity.  With information on both size and granularity of cells in the 
sample it is possible to identify them.  For example, in a whole blood 
sample, the small cells with low granularity are lymphocytes and large 
cells with high granularity are granulocytes (Figure 31).  FACS data is 
displayed on dot plots where the axes represent a measure of the scaled 
intensity of light pulses received by the detectors of the flow cytometer.  
Tests are run before an experiment to ensure that cells at both the upper 
and lower limit of what is being measured are on scale.  The machine is 
calibrated differently depending on the cell types being studied and the 
units on the axes are essentially arbitrary – cells are considered larger or 
more granular in relation to each other and objective measurements of 










The use of FACS allows for investigation of specific CD markers on a cell as it 
passes through the laser beam.  Prior to running the samples on the flow 
cytometer, the cells are labelled with antibodies for CD markers of interest.  
These antibodies are conjugated to a fluorescent chemical (fluorophore) which 
emits light of a specific wavelength when it is excited by a laser (Figure 32).  









Figure 31: Example from my data showing graphical representation of FSC Vs. SSC and 
identification of cell population based on this information.  Lymphocytes are small and less granular 
than other cells and so constitute the lower left cell population (the cluster in the far bottom left is 
debris – always present in FACS samples).  Granulocytes, macrophages etc. are larger and much 
more granular. FSC: Forward scatter (correlates to the size of a cell), SSC: Side scatter (correlates to 
cell granularity). 














Before experimental cells are run through the flow cytometer, microbeads are 
used to calibrate the machine.  Unlabelled beads are used to denote a negative 
signal and individual tubes of beads labelled with each of the fluorophores to be 
used in the experiment are used to denote a positive signal for each emission 
wavelength.  The emission wavelengths of the fluorophores will overlap to some 






Figure 32:  Schematic outlining FACS data acquisition. (Roy J Carver Biotechnology Centre, 
University of Illinois) Cells are run in single file in front of a laser.  The light hitting a cell scatters 
due to refraction and light scattered by the cell is passed through a series of dichroic mirrors, each 
reflecting a specific proportion of the beam to a corresponding detector depending on wave length. 
This separation allows individual colours emitted by a labelled cell to be detected and quantified, 
thereby identifying CD markers on the cell. For example, if a cells in a tube are incubated with 
antibodies for markers A, B and C and the three antibodies are conjugated to fluorophores that emit 
red, blue and green light respectively, high readings at the detectors for red and green light and 
nothing at the blue light detector would indicate that the individual cell passing in front of the laser 
at that given moment expresses markers A and C but not B.  Other cells in the tube may express 
different combinations of markers and could be similarly identified on an individual basis as they 
pass through the laser in single file. 




The FSC, SSC and fluorescence of each cell is integrated in the data acquisition 
software and displayed graphically.  Figure 33 shows a plot of FSC vs. APC used 
to identify cells positive for CD3 (T cells).  The cells were labelled with an 
antibody for CD3 that was conjugated to allophycocyanin (APC).  The cells 
emitting bright signals at the emission wavelength of APC can be identified as 
CD3+.  On these fluorescence plots, the FSC is not important and SSC or 
fluorescence at another wavelength could have been plotted instead.  Here we are 






Figure 33:  Example from my data showing identification of CD3+ cells in a situation where the 
cells were labelled with an anti-CD3 antibody conjugated to APC.  The Y axis is a measure of 
fluorescence at 660nm, which is the emission wavelength of this fluorophore.  Clear positive and 
negative cell populations are visible.  The 63.4 number is the % of cells of the parent cell group (in 
this case lymphocytes) that express the antigen of interest. 





CD Molecules of Interest: 
CD4 and CD8: 
Given the evidence discussed in Chapter 1 implicating T lymphocytes in 
hypertension, the focus of this chapter is to investigate the immunophenotype of 
T cells in hypertensive versus normotensive humans.  All T cells express CD3 
and because of this it is a standard marker used to pick the T cells out of the 
lymphocyte population (Figure 33).  In addition to this, I include antibody panels 
designed to compare the ratio of helper T cells to cytotoxic T cells. 
Helper T cells can be identified by expression of CD4 in addition to CD3 (they 
are CD3+CD4+ cells).  CD4 is an immunoglobulin co-receptor that works 
alongside the T cell receptor in binding to antigen-presenting cells such as 
dendritic cells.  The T cell receptor is the polymorphic binding unit that binds to 
a specific antigen whereas CD4 binds the non-variant regions of MHC class II 
(König et al., 1992, 1995).  Lck (lymphocyte-specific protein tyrosine kinase) is 
associated with the cytoplasmic tails of CD4 (Rudd et al., 1988; Barber et al., 
1989) and binding of CD4 to the MHC II/antigen complex brings Lck into range 
to phosphorylate the intracellular chains of CD3 and the T cell Receptor (Alberts 
et al., 2002).  This begins a signalling cascade resulting in intracellular calcium 
mobilisation and thereby activation of transcription factors including NFκB, 
which regulate production of proteins required for proliferation and 
differentiation of the helper T lymphocyte (Figure 34).  This is known as 
activation.  CD8 plays the same role as CD4 but on cytotoxic T cells and it 
interacts with MHC Class I rather than MHC Class II.  Only dedicated antigen-
presenting cells such as dendritic cells present antigen within the context of 




MHC Class II. MHC Class I is found on the surface of all nucleated cells and is 
the vehicle for presentation of antigen derived from intracellular pathogens or 
dysfunctional cells. 
CD45 Isotypes - CD45RO and CD45RA: 
One subset of both CD4+ and CD8+ T cells derived from 
activation/differentiation is the memory cell.  Most of the cells derived from 
proliferation of activated T cells undergo apoptosis once they lack stimulation 
from their corresponding antigen (after the pathogenic source has been 
eliminated).   The memory cell, however, along with some long-lived effector 
cells survives long-term and remains in circulation or in secondary lymph nodes 
ready to rapidly expand to large numbers of effector cells if required (Farber et 
al., 2014). 
Memory and naïve cells express different isoforms of CD45.  CD45 is expressed 
on all T cells and plays a role in cell signalling in a similar manor to CD3.  
Antigen-experienced cells express the RO isoform (CD45RO) and naïve cells 
Figure 34:  Overview of initial stage of T cell activation (figure adapted from Art Weiss Lab, 
University of California, San Francisco). Lck = Lymphocyte-specific protein tyrosine kinase, MHC= 
major histocompatibility complex, TCR = T cell receptor. 




express the RA isoform (CD45RA) (Machura et al., 2008).  Because of this, 
CD45RO Vs. CD45RA expression can and be used to test the hypothesis that 
modification of endogenous proteins, possibly as a result of oxidative stress due 
to increased ROS in hypertension, causes them to be recognised as non-self (neo-
antigen formation) and cause inflammation, which exacerbates existing 
hypertension.   
CD62L and CD197: 
Memory cells can be divided into central memory cells and effector memory 
cells.  Central memory cells express CD62L and CD197.  CD62L, also known as 
L-Selectin, is an adhesion molecule involved in the homing of lymphocytes to 
secondary lymph nodes via high endothelial venules (Warnock et al., 1998).   
High-endothelial venules are post-capillary venules located in secondary lymph 
organs (except the spleen, which lymphocytes enter via arterioles).  The 
endothelial cells of the high endothelial venules express glycosylation-dependent 
cell adhesion molecule-1 (GlyCAM-1), to which CD62L binds weakly, which 
causes the cell to roll along the wall of the venule.  This rolling is aided by 
interaction between lymphocyte function-associated antigen 1 (LFA-1), an 
integrin expressed on all lymphocytes, and intercellular adhesion molecule 1 
(ICAM-1), an immunoglobulin found on endothelial cells.  This LFA-1 to 
ICAM-1 interaction is strengthened by a conformational change in LFA-1 
caused by CD197 on the lymphocyte binding to CCL21 (DeFranco et al., 2007), 
which diffuses out from the lymphoid organ and the distinct cuboidal endothelial 
cells of the high endothelial venule.  The bond between the lymphocyte and the 
endothelium is now sufficiently strong as to allow diapedesis to occur; the cell 
leaves the venule and moves through the endothelium into the lymph node.   




Cells that are CD45RO+CD62L+CD197+ can be identified as central memory 
cells because they express the marker for memory cells and the proteins that are 
used to access the lymph node.  Cells that are CD45RO+CD62L-CD197- are 
deemed effector memory cells because they express the memory cell marker but 
lack the proteins required to access the lymph node and therefore remain in 
circulation ready to enter peripheral tissues via adhesion molecules such as P-
selectin, which is externalised by endothelial cells in response to chemicals such 
as histamine, which are released in response to perceived pathogens (Hamann & 
Syrbe, 2000). 
CD196: 
CD196 is expressed on memory T cells and is a G-protein coupled receptor for 
macrophage inflammatory Protein-3 alpha, which is a chemotactic cytokine that 
attracts lymphocytes and also neutrophils to an extent (Hieshima et al., 1997). 
This is another marker that can be used to investigate the possibility of more 
antigen-experienced cells in hypertensives as it is involved in pro-inflammatory 
signalling.  Increased expression of CD196 would be indicative of a pro-
inflammatory immunophenotype. 
CD11b: 
CD11b is found on monocytes, macrophages, neutrophils, natural killer cells and 
granulocytes such as eosinophils and basophils.  Staining these markers allows 
for quantification of cells of the innate immune system, which may be altered in 
hypertensives versus normotensives. 
 
 




Summary of Aims: 
The aim of this study was to investigate possible differences in 
immunophenotype in hypertensive humans compared to normotensive controls.  
Special focus was given to investigating differences in the proportion of cells 
that are antigen-experienced vs. those that are naïve with a view to testing the 
hypothesis that chronic antigen exposure is involved in the pathology of 
hypertension. 
Methods: 
Blood Collection:   
Blood was collected by a phlebotomist from normotensive healthy human 
volunteers and hypertensive human patients at the Clinical Research and 
Imaging Centre at Bristol University (CRIC Bristol).  The hypertensives were 
involved in a variety of studies, but all blood used for this study was taken before 
any intervention.  All participants gave informed consent for participation in the 
study and all procedures were conducted under institutionally approved protocols 
for human subjects research.  Blood was collected into vacutainers containing 
EDTA to prevent clotting and stored in a fridge at 4°C until collection later the 
same day.  8 mL was taken per patient. 
Isolation of Peripheral Blood Mononuclear Lymphocytes: 
In the case of each sample, blood was transferred into 50ml Falcon tubes and 
diluted 1:1 with HBSS+HEPES (stock solution made up by putting 10ml HEPES 
into 500mL HBSS).  This mixture was the layered carefully onto 15ml of 
histopaque 1077 (Sigma cat # 10771-100ml) in another 50ml Falcon tube.  These 
tubes were then spun at 1600rpm for 30 minutes with the centrifuge break off, at 
room temperature.  The buffy coat layer at the interface between the plasma and 




the red cells was collected with a disposable glass pasteur pipette (Corning cat 
#7095D-9) and the cells were diluted with HBSS+HEPES to 50 ml in a 50ml 
Falcon tube.  These were spun at 300g (1500rpm) for 10 minutes at room 
temperature, the supernatant was discarded and the cells resuspended in 50ml 
HBSS+HEPES.  They were then spun again for 20 mins at 200g (1000rpm) in 
order to remove platelets, resuspended in 50ml HBSS+HEPES and washed again 
with a 10 minute spin at 300g.  Then cells were then resuspended in 3ml FACS 
buffer, which consisted of 0.5% bovine serum albumin (Sigma) in PBS 
(Dulbecco tablets).  The cells were then counted using trypan blue (Sigma cat # 
T8154-100ML) staining.  Trypan blue is a dye that does not enter live cells as it 
cannot cross the cell membrane.  This allows live cells to be quantified more 
easily against a blue background. 
Trypan Blue Staining: 
For each tube, a 20μL of sample of the cell suspension was added to 20μL of 
trypan blue in small Eppendorf tubes and mixed via pipette.  The cell suspension 
was then placed on a haemocytometer and the cells were counted using an 
inverted Leica microscope.  One million cells were put into three 5ml, round 
bottomed FACS tubes (FisherScientific cat # 14-959-2A) – one million cells for 
each of the three antibody panels that were to be used per animal - and topped up 
to 2ml with FACS buffer.  The tubes were spun at 1200rpm for 10 mins, the 
supernatant was vacuum-aspirated and the cells were resuspended in 1ml FACS 
buffer ready for antibody staining. 
 
 





The four antibody panels that were used are displayed in Table 4. 
 CD marker Fluorescent conjugate Reason for interest in CD marker 
Panel A CD3 APC Denotes T cell 
 CD45RO FITC Expressed by antigen-experienced cells 
 CD4 PacBlue Denotes helper T cell 
 CD8a APC/Cy7 (tandem) Denotes cytotoxic T cell 
 CD62L PE Involved in homing to lymph nodes 
    
Panel B CD3 APC Denotes T cell 
 CD62L PE Involved in homing to lymph nodes 
 CD197 AF488 Involved in homing to lymph nodes 
 CD4 PacBlue Denotes helper T cell 
 CD8a APC/Cy7 (tandem) Denotes cytotoxic T cell 
    
Panel C CD3 APC Denotes T cell 
 CD45RO FITC Expressed by antigen-experienced cells 
 CD45RA AF700 Expressed by naive cells 
 CD196 PE Is pro-inflammatory 
    
Panel D CD4 PacBlue Denotes helper T cell 
 CD8a PE/Cy7 (tandem) Denotes cytotoxic T cell 
 CD11b PerCP/Cy5.5 (tandem) Expressed by cells of innate immune system 
 CD69 BV650 Activation marker 
 
 
The mastermix for each panel was made up with 1.5 μL of each appropriate 
antibody per subject in 100μL of FACS buffer per sample plus 10μL extra for 
every 6 samples in order to account for loss due to multiple pipette-tip changes. 
E.g.  Blood collected from 2 people:   
4 panels for 2 subjects= 8 samples.  Mastermix for each panel is made up by 
putting 3μL of each appropriate antibody into 220μL of FACS buffer. 
The antibody mastermix tubes were mixed using a vortex machine and then 
100μL of appropriate mastermix was added to the corresponding sample tubes  
Table 4:  Display of antibody panel composition.  Consult glossary of terms for full 
names of fluorophores. 




E.g.  Blood collected from 2 subjects: 
2x Panel A, 2x Panel B, 2x Panel C, 2x Panel D tubes, each with one million 
cells from corresponding subject suspended in 1ml FACS buffer and 100μL of 
appropriate mastermix added for staining. 
Tubes were wrapped in aluminium foil and placed in a fridge at 4°C for 20 
minutes.  They were then topped up to 2ml with FACS buffer and spun at 
1200RPM for 10 minutes.  The supernatant was vacuum-aspirated and the 
stained cells were resuspended in 250μL FACS buffer and 62.5μL 
paraformaldehyde (PFA).  The PFA was included in order to fix the cells so that 
they can be analysed at a later date.  The cells were wrapped in foil and 
refrigerated until they were run on a flow cytometer (BD LSRII) not more than 
one week later. 
Flow Cytometry: 
Compensation:   
When designing an antibody panel for FACS it is important to choose 
fluorescent conjugates that have as little spectral overlap as possible.  The 
detection range in flow cytometry is limited to ~370nm-~800nm and although 
conjugates used are known to exhibit bright emissions at a specific wavelengths 
they also emit some light across a range of wavelengths on either side of the 
spectrum - they have broad emission spectra. 




An example of spectral overlap is shown in Figure 35:
 
Figure 35:  Example of spectral overlap of emission spectra of commonly used fluorophores.  Diagram 
adapted from ebioscience. 
In Figure 35 we see that FITC emissions spill into the range in which the flow 
cytometer will be detecting PE.  Left unchecked, running samples stained with 
FITC would also give false positive readings for PE. 
When performing multicolour cytometry it is inevitable that some spectral 
overlap will occur between the various colours that are used, even if care has 
been taken to minimize overlap during panel design.  Because of this, before 
running samples on a flow cytometer it is essential to run compensation controls 
to account for overlap of emission spectra from the various fluorescent 
conjugates that are used in an experiment.   
Compensation controls use beads stained with each of the fluorescent conjugates 
used in the experiment (positive controls), as well as beads that are unstained 
(negative controls).  These beads are run one colour at a time and the software 
(BD FACSDiva) uses an algorithm to subtract overlapping emissions from the 
positive readings for each of the individual conjugates so that an individual 
conjugate can be detected accurately. 
FITC PE 




Preparation of the beads for compensation controls was done on the day the 
samples were to be run on the flow cytometer.  Antibody solutions were made up 
by adding 1.5μL of each antibody for each fluorescent conjugate used in the 
experiment to 100μL FACS buffer (10 tubes total- FITC, APC, PE, PacBlue, 
APC-Cy7, AF488, AF700, PE-Cy7, PerCP-Cy5.5 and BV650).  Separate FACS 
tubes were prepared for each fluorescent conjugate and one drop each of positive 
and negative compensation beads (BD cat# 552845) were added to each.  The 
appropriate antibody solution was added to each of the tubes and they were 
mixed via vortex.  The tubes were left at room temperature until they were used 
for compensation controls ~20 minutes later. 
All sample tubes were vortexed thoroughly before use on the flow cytometer, as 
cells collect at the bottom of the tubes after being left undisturbed in the fridge 
for several days and require resuspension.  Data was collected in BD FACSDiva.  
CD3 (APC) was used as a stopping gate which ensured that 10,000 CD3+ cells 
were collected for each sample except in the case of panel D (which did not 
contain antibodies for CD3) in which case approximately double the number of 
total cells was collected in relation to the other panels.  A cell population was 
deemed positive for an antigen if it had a higher fluorescence than the unstained 
control.  Once data collection was complete it was exported into FlowJo (Tree 
Star Inc.) for analysis. 
Gating/Analysis: 
Gating: 
Gating refers to the selection of a cell population within a flow cytometry data 
set as presented in a dot plot (see for example Figures 31 and 33 shown 
previously).  Cells can be identified base on size and granularity (Figure 31) or 




by their expression of a particular antigen or antigens inferred by the 
measurement of fluorescent labels attached to said antigens (Figure 33).  Gating 
onto identified cell populations allows quantification of the proportion of cells in 
a sample expressing antigens of interest, thereby allowing the cell type to be 
determined based on knowledge of cell biology. 
FMO: 
A fluorescence minus one (FMO) control was performed to assist with gating.  
In an FMO, cells are stained with versions of each panel with one of the 
antibodies missing and the tubes are run on the flow cytometer as normal.  This 
produces plots that are useful for gating, especially if positive and negative cell 
populations are close together due to low levels of expression of a target antigen 
or if a fluorescent conjugate is not very bright. 
An example from one of my FMOs is shown in Figure 36.  In this example, 
Panel C was run without FITC, the fluorochrome that provided the most difficult 
positive populations to gate onto (Panel A) and then with FITC (panel B). 





Figure 36: Flow cytometry dot plots showing A: Antibody panel C run without FITC and B: With FITC 
included.  Comparing the two plots allows the identification of cell groups that are labelled with FITC since 
cells brighter than those in the negative cell population can be considered positive (note the logarithmic 
scale on the Y axis).  The Y axis shows the intensity of the light emitted by FITC, known because the 
wavelength of the light emitted by the fluorophore is known and the fluorophores used in multicolour 
panels are chosen in order to minimize spectral overlap-any overlap that does exist is mitigated using 
compensation controls as outlined earlier. The X axis shows forward scatter, which correlates to the size of 
the cells. The ‘gate’ denoting the boundary between positive and negative populations was placed 
manually, which is why FMO controls are helpful – user bias is reduced. 
A 
B 






In the FMO, we know that no FITC is present so when we compare it to 
complete experimental samples, everything brighter than the cell population 
shown on the FMO can be considered positive (there are a few clearly 
anomalous results that are excluded in the FMO). Having a plot demonstrating 
what panel C looks like without FITC included allows for more confident gating 
on to the positive cell group in the experimental samples.  This is especially 
valuable when the positive and negative cell groups are touching as in this 
example.   
Gating Strategy: 
For Panels A-C an initial gate sought to pick out the lymphocytes based on their 
size and granularity (FSC Vs. SSC).  Then T cells were isolated by gating cells 
positive for APC (CD3+ cells).  These cells are T lymphocytes.  Further gating 
was used to identify various T-cell subtypes depending on the antibody panel.   




Figure 38: T cells within the lymphocyte population identified based on their expression of CD3, 
determined by fluorescent emission from APC-conjugated antibodies for CD3. 











Drilling down further allows identification of specific cell populations: 
Panel A Specific: 
  
                            
 




Figure 37: Lymphocyte population identified base on the forward scatter (size) and side scatter 
(granularity). 





Figure 39: Identification of Helper T cells within the T cell population based on their expression of CD4, 
determined by fluorescent emission from Pacific Blu-conjugated antibodies for CD4. 
Figure 40: Identification of cytotoxic T cells within the T cell population based on their expression of 
CD8a, determined by fluorescent emission from APC/Cy7-conjugated antibodies for CD8a. 





Figure 41: Identification of T cells expressing CD62L within the Helper T cell population, determined by 
fluorescent emission from PE-conjugated antibodies for CD62L. 
Figure 42: Identification of cells expressing CD62L within the cytotoxic T cell population determined by 
fluorescent emission from PE-conjugated antibodies for CD62L. 




   Panel B specific:  
 
Figure 43: Identification of cells expressing CD197 within the T cell population determined by 
fluorescent emission from FITC-conjugated antibodies for CD197. 
 
Figure 44: Identification of cells expressing CD197 within the Helper T cell population determined by 
fluorescent emission from FITC-conjugated antibodies for CD197. 
 
 




Panel C specific: 
Figure 45: Identification of cells expressing CD197 within the Cytotoxic T cell population determined by 
fluorescent emission from FITC-conjugated antibodies for CD197. 
 
Figure 46: Identification of memory T cells within the T cell population determined by fluorescent emission 
from FITC-conjugated antibodies for CD45RO. 
 







Figure 47: Identification of naive T cells within the T cell population determined by fluorescent 
emission from AF700-conjugated antibodies for CD45RA. 
 
Figure 48: Identification of cells expressing CD196 within the T cell population determined by 
fluorescent emission from PE-conjugated antibodies for CD196 
 




Panel D specific: 
All cells were included in the initial gate when quantifying CD11b+ cells as 
these cells are not T Lymphocytes but cells of the innate immune system such as 
monocytes, granulocytes, macrophages, and natural killer cells. The cluster of 
debris in the bottom left of the initial FSC Vs. SSC plot is excluded but all cells 
included in the initial gate. 
An example of the initial gate for Panel D is shown in Figure 49: 
The ‘All cells’ gate was the initial gate, rather than the lymphocyte gate and no 
subsequent gate was required before gating on CD11b+ cells (Figure 50). 
Figure 49: Initial gate for Panel D.  All cells are included in the gate, the cluster of debris in the 
bottom left is excluded.   
 




                       
Measurement of CD69 expression on both CD4+ and CD8a+ cells was attempted 
with panel D but failed. 
The % of T cells expressing each of the antigens measured or % of all cells 
expressing CD11b from each subject were averaged and subjects were grouped 
into normotensive (NTN) and hypertensive (HTN) based on blood pressure data 
collected at the Clinical Research and Imaging Centre at Bristol University 
(CRIC Bristol).  They were further subdivided based on sex.  Subjects that had 
recently taken medication known or suspected to effect immunophenotype (such 
as ibuprofen) were excluded from the study. 
 
Figure 50: identification of cells of all sizes (hence the x-axis forward scatter spread) expressing CD11b, 
determined by fluorescent emission from PerCP/Cy5.5-conjugated antibodies for CD11b. 
 





Significant Differences in T-cell Phenotype of Human Hypertensives 
Compared to Normotensive Controls in Males but Not in Females: 
CD62L expression on CD8a+ cytotoxic T cells was significantly reduced in 
hypertensive males, P=0.017 (Figure 51C) but not in females (Figure 52C).  
Similarly, CD197 expression was significantly reduced on CD8a+ cytotoxic T 
cells in hypertensive males compared to normotensive controls, P=0.013 (Figure 
51E).  This finding was not observed in females. (Figure 52E). 
Expression of the RO isotype of CD45 on T cells was increased in hypertensive 
human males compared to normotensive controls, P=0.006 (Figure 51F).  The 
inverse was seen in the case of the RA isotype; CD45RA expression on T cells 
was decreased in hypertensives compared to normotensive controls, P=0.009 
(Figure 51F).  The same trends were observed in females but the results were not 
statistically significant (Figure 52F). 
An increase in the percentage of T cells expressing CD196 was observed in 
hypertensive human males compared to normotensive controls, P=0.020 (Figure 
51F).  This difference was not observed in females (Figure 52F). 
No Significant Differences in Expression of Several Proteins in T-cells and 
Cells of the Innate Immune System Between Hypertensive and 
Normotensive Humans: 
No differences in the percentage of T cells expressing CD4 or CD8a were 
observed between hypertensive patients and normotensive controls in either the 
male (Figure 51A) or female (Figure 52A) groups. 




In addition, no significant difference in the percentage of CD4+ helper T cells 
expressing CD62L was observed between hypertensive patients and 
normotensive controls in either the male (Figure 51B) or female (Figure 52B) 
groups.  No significant difference in expression of CD197 was observed on 
CD4+ helper T cells between the hypertensive or normotensive groups (Figures 
51D and 52D). 
Finally, no difference in the percentage of all leukocytes expressing CD11b were 
observed between hypertensive patients and normotensive controls in either the 
male (Figure 51G) or female (Figure 52G) groups.  






























* * * 
* 
Figure 51:  T cell phenotype in Hypertensive human males Vs. aged-
matched normotensive controls.  A:  CD4+ Vs. CD8a+ cells.  B & C:  
CD62L expression on CD4+ and CD8a+ cells respectively.  D & E:  
Expression of CD197 on CD4+ and CD8a+ cells respectively.  F:  
CD45RO Vs CD45RA and CD196 expression on T cells.  G:  % of all 
leukocytes expressing CD11b.  Hypertensives exhibit a significant 
reduction of CD62L and CD197 on CD8a+ cells, a significant increase 
in CD45RO+ T cells, a significant reduction in CD45RA+ T cells and 
a significant increase in T cells expressing CD196.  HTN n=32   NTN 
n=18   Error bars represent SEM. P-values determined by T-test were 
as follows C: 0.017, E: 0.013, F: CD45RO: 0.006 CD45RA: 0.009, 
CD196: 0.020 






Figure 52:  T cell phenotype in Hypertensive human females Vs. 
aged-matched normotensive controls.  A:  CD4+ Vs. CD8a+ cells.  B 
& C:  CD62L expression on CD4+ and CD8a+ cells respectively.  D 
& E:  Expression of CD197 on CD4+ and CD8a+ cells respectively.  
F:  CD45RO Vs CD45RA and CD196 expression on T cells.  G:  % 
of all leukocytes expressing CD11b.  No significant differences were 
observed.  HTN n= 31, NTN n = 23 Error bars represent SEM. P-










Increased CD45RO+ T-Cells and Reduced CD45RA+ T-Cells in 
Hypertensive Human Males: 
The fact that hypertensive human males exhibited a significant increase in the 
percentage of T cells expressing the RO isotype of CD45 and a significant 
decrease in expression of the RA isotype (Figure 51) supports the hypothesis that 
chronic antigen exposure is implicated in either the generation and/or 
maintenance of hypertension (Figure 7) since the RO isotype is expressed on 
antigen experienced cells and the RA isotype is expressed on naïve cells, as 
discussed in Chapter 1. 
My study was descriptive and does not provide any mechanistic insight into why 
these changes occur in hypertension.  However, as referenced in Chapter 1, there 
is evidence that due to oxidative stress (which is increased in hypertension), 
isoketals accumulate in dendritic cells, which cause CD8a+ T cells to adopt a 
pro-inflammatory phenotype characterised by production of INF-γ and IL-17 
(Kirabo et al., 2014).  
IFNγ is an important pro-inflammatory cytokine with a variety of functions 
(Schroder et al., 2004).  It stimulates macrophages, resulting in an increase of 
antigen-presenting activity as well as increasing lysosome activity, it activates 
natural killer cells, it activates inducible nitric oxide synthase, increases the 
expression of MHCI on all cells and MHCII on antigen-presenting cells (thereby 
promoting antigen collection, processing and presentation, which leads to 
amplification of the inflammatory signal) and it promotes leukocyte adhesion 
and binding required for recruitment of leukocytes to sites of inflammation. 




Another pro-inflammatory cytokine of note is IL-17. It is mostly produced by 
specialised TH17 helper T cells but is also produced by activated CD8+ cytotoxic 
T cells.  IL-17 promotes the synthesis of other cytokines such as IL-6 and TNFα 
by a variety of other cells including endothelial cells and macrophages.  
Although IL-17 is important mediator of helpful and necessary inflammation, it 
is also implicated in auto-immune disease (Kuwabara et al., 2017) and the fact 
that hypertension promotes a shift of CD8+ cytotoxic T cells to a pro-
inflammatory phenotype, resulting in production of INF-γ and IL-17, exacerbates 
hypertension as discussed in Chapter 1 (pages 36 and 37). 
The increased ratio of antigen-experienced to naïve T cells I observed supports 
the hypothesis that hypertension causes the production of reactive oxygen 
species which modify endogenous proteins such that they are no longer 
recognised as self and, hence, an auto-immune inflammatory response occurs.  
This is pro-hypertensive as discussed in Chapter1.  
Reduced Expression of CD62L and CD197 in Hypertensive Human Males: 
The observed reduction of CD62L and CD197 expression in hypertensive human 
males (Figure 51) is further evidence that the proportion of T cells that are 
antigen-experienced is increased in hypertension.  Specifically, these findings 
point to a greater percentage of effector memory T cells in the circulation in 
conditions of hypertension as these proteins are shed by antigen-experienced 
cells which remain in the peripheral circulation ready to encounter their 
corresponding antigen and rapidly differentiate into effector cells in order to 
combat an invading pathogen, or possibly contribute to auto-immune disease.  
Statistically significant differences in the expression of these two proteins were 
observed in CD8a+ cytotoxic T-cells specifically (Figure 51 panels C and E).  




An increase in the proportion of cytotoxic T cells that are in the circulation of 
hypertensive males increases the possibility that these cells could enter the brain 
parenchyma via a compromised BBB (Biancardi & Stern, 2016) and disrupting 
neuronal signalling in brain nuclei such as the PVN and the RVLM, thereby 
driving hypertension, as described in Chapter 1 (pages 51-54).  Pro-
inflammatory cytokines (such as TNFα, IL‐1β, IL‐6, IFNγ and IL-17) released 
by infiltrating T cells could activate microglia in the CNS, exacerbating 
inflammation and production of ROS within the CNS. This promotes 
neurohumoral excitation, which increases sympathetic outflow and is pro-
hypertensive (Kang et al., 2009; Cardinale et al., 2012; Sriramula et al., 2013). 
Increased incidence of immune cells infiltrating the CNS is one way in which 
reduced expression of CD62L and CD197 on T cells may be contributing to 
hypertension.   
Due to the increase in pro-inflammatory cytokines in hypertension, in particular 
IL-17 and IFNγ, vascular infiltration of T cells is increased (Madhur et al., 
2010).  An increase in activated cells in the circulation makes this more likely to 
happen.  This promotes pathological vascular remodelling (vessel hardening) 
which prevents vessels dilating properly, increasing blood pressure through 
greater vascular resistance.  The simple fact that hypertensive males have a 
greater number of cytotoxic T cells circulating within the vessels means that the 
damage they do as outlined in Chapter 1 is more severe.  This includes inhibition 
of NO-mediated vasodilation and promotion of T-cell-derived-ANG-II-mediated 
vasoconstriction.   
 
 




Increased Expression of CD196 in Hypertensive Human Males: 
Expression of CD196 was increased in hypertensive human males (Figure 51).  
CD196 is a receptor for Macrophage Inflammatory Protein-3 (MIP-3), which is a 
chemokine that is a powerfully chemotactic for lymphocytes (Baba et al., 1997) 
and is therefore involved in pro-inflammatory signalling so this finding provides 
further evidence that a pro-inflammatory T-cell phenotype is associated with 
human hypertension.  
No Significant Differences in T-Cell Phenotype between Normotensive and 
Hypertensive Human Females: 
It is important to note that there was no significant differences in T-cell 
phenotype between hypertensive and normotensive women (Figure 52).  This 
may be due to protective female hormones.  Post-menopausal women have 
higher blood pressure than age-matched women who are pre-menopausal (Weiss, 
1972; Staessen et al., 1989) and women suffering with premature ovarian failure 
also suffer with hypertension at a higher rate than age-matched women with 
healthy ovaries (Sandberg & Ji, 2012).  There are many known differences in the 
control of blood pressure and the pathology of hypertension between men and 
women, such as females having greater levels of NO in the vasculature or males 
having enhanced vasoconstriction (Zimmerman & Sullivan, 2013). 
As discussed earlier, adoptive transfer of T cells from WT mice into RAG-/- mice 
restores their propensity to develop hypertension in response to ANGII infusion 
(Guzik et al., 2007).  Both the RAG-/- mice and the donor WT mice in this study 
were male.  Interestingly, the same procedure does not restore vulnerability to 
ANGII mediated hypertension in female mice (Pollow et al., 2014).  Further, if 
female CD3+ T cells are transferred into male RAG-/- mice, the subsequent  





ANGII-induced hypertensive response is significantly less severe than it is when 
male donor cells are utilised (Ji et al., 2014). 
Tregs play a pivotal role in regulating healthy immune responses to pathogens as 
well as preventing auto-immune disease.  They produce IL-10, an anti-
inflammatory cytokine which inhibits synthesis of pro-inflammatory cytokines 
(Chen & Liu, 2009).  Adoptive transfer of Tregs into age-matched male mice 
limits ANGII-induced increases in blood pressure (Barhoumi et al., 2011).  This 
combined with the fact that castration of healthy men reduces circulating Tregs  
(Page et al., 2006) suggests a deleterious role for testosterone in hypertension 
and may begin to explain why men are more prone to hypertension than women.  
It may also offer a partial explanation as to why I observed a pro-inflammatory 
immunophenotype in hypertensive men but not in women.  Fitting with this, 
estrogen stimulates the production of Tregs in mice and estrogen-stimulated 
differentiation of helper T cells into Tregs is blocked by estrogen antagonists (Tai 
et al., 2008).  Taken together these studies suggest that testosterone is pro-
hypertensive and oestrogen protects against hypertension.  However, the reality 
is not that simple; gonadectomy increases inflammatory markers in both males 
and females (Tipton et al., 2014) suggesting that both sex hormones are anti-
inflammatory.  More research is needed to understand this. 
The prevailing cytokine milieu affects the differentiation of naïve T cells.  High 
concentrations of TGF-β and low concentrations of IL-6 promote differentiation 
into TH17 cells (which secrete pro-inflammatory IL-17) and low concentrations 
of TGF-β combined with high concentrations of IL-6 promote differentiation 




into Tregs (Zheng, 2013).  The ratio favouring Tregs prevails in females and as 
such females produce more Tregs (Tipton et al., 2014). 
Building upon the sex differences noted above, when I compared the 
immunophenotypes of pre and post-menopausal hypertensive women (see 
Apendix A) I found that the post-menopausal women exhibited trends such that 
their immunophenotype was closer to that of men than pre-menopausal women.  
Young men disproportionately control blood pressure by controlling peripheral 
vascular resistance, whereas young women preferentially maintain blood 
pressure by controlling cardiac output (Hart et al., 2012).  Young 
(premenopausal) women have a weak relationship between muscle sympathetic 
nerve activity and blood pressure compared to men (Charkoudian et al., 2017).  
This is partly due to estradiol augmenting the vasodilator response mediated by 
β-adrenoreceptors (Charkoudian et al., 2017).  SNA increases with age and as 
women age, menopause results in the loss of female hormones, SNA, peripheral 
resistance and blood pressure become more closely related, in a manner 
comparable to men (Charkoudian et al., 2017).   
No Difference in Expression of CD11b in Leukocytes of Hypertensive Vs. 
Normotensive Humans: 
No changes were observed in expression of CD11b between hypertensive and 
normotensive groups in either males or females (Figures 51 and 52).  This 
protein is expressed by a wide variety of cells of the innate immune system as 
discussed earlier.  Therefore, this observation suggests that it is the adaptive 
immune response specifically that is contributing to hypertension. 
 
 




Limitations and Further Study: 
Overall my data support the neoantigen hypothesis (Harrison et al., 2011) and 
the notion that a pro-inflammatory immunophenotype maintains and/or 
exacerbates hypertension in human males.  Although I gained some insight into  
Pre vs. post-menopausal women, the n was low when the women were split up to 
assess this.  In the future it would be interesting to take a large cohort of women 
and look at this in more detail.  Also, it would be useful to expand the antibody 
panels to include additional markers of interest such as CD44, an activation 
marker involved in leukocyte recruitment and secretion of cytokines (Sneath & 
Mangham, 1998) and CD69, an early activation marker (Lindsey et al., 2007) 
that controls T-cell differentiation into TH-17 cells (Fuente et al., 2014).  
Inclusion of antibodies for these markers would allow for better characterisation 
of the immunophenotype of T cells in hypertension.    
It should be noted that many of the hypertensive patients used in this study were 
taking anti-hypertensive medications and these medications had the potential to 
act as confounding factors in the study.  It is not possible to recruit large 
numbers of untreated hypertensive due to moral and ethical concerns, but 13 of 
the males initially entering the study as normotensive volunteers were in fact 
found to be hypertensive during screenings and therefore constituted a small 
group of untreated hypertensives to study since blood was taken from them 
before they moved on to treatment.  Analysing these patients alone yielded the 
same findings as when all patients were taken together (See Appendix B), 
indicating that the medications the patients were taking did not influence 
immunophenotype.  Any patient that was taking anti-inflammatory drugs such as 
ibuprofen or diclofenac was excluded from this study. 




Chapter 5:  Effect of mGluR5 Modulation on T-Cell 
Phenotype in Rats 
Introduction: 
Given the evidence that T cells are involved in hypertension (see Chapter 1) and 
that hypertensive human males exhibit an altered immunophenotype that is 
indicative of an increase in antigen-experienced cells and increased proportion of 
activated cells (see Chapter 4), I intended to investigate whether there is also an 
altered immunophenotype in SHR compared to normotensive Wistar controls.  I 
used FACS as discussed in Chapter 4 to examine leukocytes isolated from whole 
blood collected from the tail veins of the animals. 
In addition to comparing the immunophenotypes of the two strains of rat without 
any other intervention, I intended to investigate how mGluR5 modulation effects 
it.  In chapter 1 I provided examples of situations in which immunosuppressive 
therapies caused reductions in blood pressure and in chapter 3 I presented data 
showing that modulation of mGluR5 causes changes in blood pressure, at least in 
the short term.  In this chapter I observed the immunophenotype of the animals at 
baseline, after vehicle treatment, after drug treatment and one week after drug 
treatment (washout).  It is possible that the effects of mGluR5 modulation on 
blood pressure manifest, at least in part, due to changes in the immune system 
resulting from altered sympathetic outflow.  Does the blood pressure increase 
caused by positive allosteric modulation of mGluR5 coincide with increased 
activation of T cells and is the reverse true in the case of mGluR5 antagonism?  I 
investigated these questions in this chapter. 
 




Markers of Interest: 
CD4 and CD8a: 
As was the case in Chapter 4, I intended to determine the proportions of helper 
and cytotoxic T cells circulating in the subjects and I used CD4 and CD8 
respectively as markers to identify these leukocyte subtypes. 
CD44: 
CD44 is a transmembrane glycoprotein involved in a variety of functions 
including lymphocyte migration and activation.  It is used as a marker for 
antigen experienced cells in rodents (Sneath & Mangham, 1998).  The protein is 
expressed on both central and effector memory cells and is more commonly used 
as a marker of these cells in rodents than CD45RO. 
CD62L: 
As discussed in Chapter 4, CD62L, is an adhesion molecule involved in the 
homing of lymphocytes to secondary lymph nodes via high endothelial venules.  
It is present on naïve memory cells as they need to enter secondary lymph organs 
in order to encounter antigen and it is also present on central memory cells as 
they need to return to locate to secondary lymph organs where they will reside 
until re-encountering their antigen in which case they rapidly expand to many 
effector cells in order to neutralise the source of the antigen.  The absence of 
CD62L is used to differentiate between CD44+ effector and CD44+ central 
memory cells; the latter lack CD62L and remain in circulation and tissues.   
CD3+CD4+CD44+CD62L+ = Central memory helper T cell 
CD3+CD8+CD44+CD62L- = Effector memory cytotoxic T cell 






CD11c is a marker found on monocytes, macrophages and neutrophils and 
CD11b is found on these cells as well as other cells of the innate immune 
system, as mentioned in Chapter 4.  Staining for both markers allows for 
quantification of cells of the immune system, numbers of which may vary 
between the hypertensives and normotensives as a result of activity by helper T 
cells (cytokine production etc.). 
Summary of Aims: 
The aim of this study was to investigate the effect of modulation of mGluR5 on 
immunophenotype and to expose any possible differences in immunophenotype 
in SHR compared to normotensive controls.  As in Chapter 4, focus was given to 
investigating differences in the proportion of cells that are antigen-experienced 
vs. those that are naïve with a view to testing the hypothesis that chronic antigen 
exposure is involved in the pathology of hypertension.  In this instance, CD44 
was used as the key indicator for activation / antigen experience and CD62L was 
used to differentiate between central and effector memory cells.  Upregulation of 
CD44 and downregulation of CD62L would be indicative of an inflammatory 
phenotype in which there are more antigen-experienced cells. 
Methods: 
Blood Collection: 
All animal experiments were performed in accordance with institutional 
guidelines and the UK Home Office (Scientific Procedures) Act (1986) with 
project approval from the University of Bristol, University ethics of research 




committee, under Home Office personal license number ICCF4B573 and project 
license number 70/7868. 
Blood was collected at four time-points during the in vivo mGluR5 studies in 
Chapter 3: The animals used in this study were those same animals and no 
additional drugs were given for the purpose of this study.  The four blood-
collection time points were: At the end of the week of baseline recordings (no 
drugs administered), after one week of vehicle treatment, after one week of drug 
treatment and after one week of washout. 
Blood for the first three time-points was collected via tail vein bleed.  The 
animals were placed into a perspex box (custom-made with air holes, 
approximately 70% the volume of a standard home cage) warmed via an electric 
heat pad to approximately 27°C for approximately 10 minutes before being 
moved to a restraint tube with the tail protruding.  The tail was quickly cleaned 
with warm water (approx. 40°C) and (Hydrex Pink Surgical Scrub) before 
venous insertion of a 24G Terumo Sureflo IV catheter.  1ml of blood was then 
allowed to drip into an Eppendorf tube containing 150μL of EDTA to prevent 
clotting.  In the event that a bleed was unsuccessful a fresh cannula was used to 
make up to two additional attempts.  After bleeding was completed, sterile gauze 
was held over the wound until bleeding stopped and the tail was carefully 
cleaned before the animal was returned to its home cage.  Collected blood was 
immediately stored in a fridge at 4°C. 
For the fourth time-point (post-washout) blood was collected via cardiac 
puncture.  The animals were given an overdose of sodium pentobarbital 
administered via intraperitoneal injection.  In each case the animal’s chest was 
opened upon loss of the foot pinch reflex but before death and blood collected 




from the heart via an EDTA-rinsed needled inserted intraventricularly.  The 
blood was transferred to an Eppendorf tube containing 150μL of EDTA to 
prevent clotting and immediately placed in a fridge at 4°C. 
FACS: 
Red Blood Cell Lysis: 
The blood for each animal was transferred into a 50ml Falcon tube and 10 ml of 
red blood cell lysis buffer was added (eBiosciences cat#00-4300-54).  The tubes 
were agitated and then left to sit at room temperature for 10 mins before they 
were topped up to 50ml with PBS (Dulbecco tabs) and spun at 1200RPM for 10 
mins.  The supernatant was discarded and the above process repeated. 
After the 2nd wash the cells were resuspended in 3ml of FACS buffer and cells 
were counted using trypan blue staining as in Chapter 4. 
Antibody Staining: 
The three antibody panels that were used are displayed in Table 5: 
 CD marker Fluorescent conjugate Reason for interest in CD marker 
Panel A CD3 PE Denotes T cell 
 CD45 V450 Denotes T cell 
 αβTCR FITC Denotes T cell 
 CD62L AF647 Involved in homing to lymph nodes 
    
Panel B CD3 PE Denotes T cell 
 CD45 V450 Denotes T cell 
 CD44 FITC Expressed by antigen-experienced cells 
 CD11 EF660 Expressed by cells of innate immune system 
    
Panel C CD3 PE Denotes T cell 
 CD45 V450 Denotes T cell 
 CD4 APC Denotes helper T cell 
 CD8 PerCP Denotes cytotoxic T cell 
 
Table 5: Display of antibody panel composition.  Consult glossary of terms for full names of fluorophores. 




The mastermix for each panel was made up with 1.5 μL of each appropriate 
antibody per sample in 100μL of FACS buffer per sample plus 10μL extra for 
every 6 tubes in order to account for loss due to multiple pipette-tip changes. 
E.g.  Blood collected from 6 animals:   
3 panels for 6 animals=18 samples.  Mastermix for each panel is made up by 
putting 9μL of appropriate antibody into 1830μL of FACS buffer. 
The antibody mastermix tubes were mixed using a vortex machine and then 
100μL of appropriate mastermix was added to the corresponding sample tubes  
E.g.  Blood collected from 6 animals: 
6x Panel A, 6x Panel B, 6x Panel C tubes, each with one million cells from 
corresponding animal suspended in 1ml FACS buffer and 100μL of appropriate 
mastermix added for staining. 
Tubes were wrapped in aluminium foil and placed in a fridge at 4°C for 20 
minutes.  They were then topped up to 2ml with FACS buffer and spun at 
1200RPM for 10 minutes.  The supernatant was vacuum-aspirated and the 
stained cells were resuspended in 250μL FACS buffer and 62.5μL 
paraformaldehyde (PFA).  The PFA was included in order to fix the cells so that 
they can be analysed at a later date.  The cells were wrapped in foil and 
refrigerated until they were run on a flow cytometer (BD LSRII) not more than 
one week later. 
Flow Cytometry:            
Preparation of the beads for compensation controls was done on the day the 
samples were to be run on the flow cytometer.  Antibody solutions were made up 
by adding 1.5μL of each antibody for each fluorescent conjugate used in the 




experiment to 100μL FACS buffer (7 tubes total- V450, PE, FITC, AF647, APC, 
EF660 and PerCP).  Separate FACS tubes were prepared for each fluorescent 
conjugate and one drop each of positive and negative beads (BD cat# 552845) 
were added to each.  The appropriate antibody solution was added to each of the 
tubes and they were mixed via vortex.  The tubes were left at room temperature 
until used for compensation controls ~20 minutes later. 
All sample tubes were vortexed thoroughly before use on the flow cytometer, as 
cells collect at the bottom of the tubes after being left undisturbed in the fridge 
for several days and require resuspension.  Data was collected in BD FACSDiva.  
CD3 (V450) was used as a stopping gate and 10,000 CD3+ cells were collected 
for each sample.  A cell population was deemed positive for an antigen if it had a 
higher fluorescence than the unstained control.  Once data collection was 
completed it was exported into FlowJo (Tree Star Inc.) for analysis. 
Gating/Analysis: 
After samples were run on the flow cytometer, analysis was performed using 
FlowJo software (V10).  For all antibody panels an initial gate sought to pick out 
the lymphocytes based on their size and granularity (FSC Vs. SSC).  Then T 
cells were isolated using a plot of V450 Vs. PE and gating the cells that were 
positive for both.  These cells express both CD45 and CD3, confirming them as 
T lymphocytes.  Further gating was used to identify various T-cell subtypes 
depending on the antibody panel.  An FMO control experiment was performed to 
assist with gating as in Chapter 4. 




Lymphocyte gate was drawn as shown in Figure 53: 
 
T cells were identified as shown in Figure 54: 
 
Figure 53: Lymphocyte population identified base on the forward scatter (size) and side scatter 
(granularity). 
 
Figure 54: T cells within the lymphocyte population identified based on their expression of both CD3 
and CD45, determined by fluorescent emission from both PE-conjugated antibodies for CD3 and 
V450-conjugated antibodies for CD45. 
 




Panel A specific: 
Panel B Specific: 
Initial gate example: 
The ‘All cells’ gate is the initial gate, rather than the lymphocyte gate and no 








Figure 55: CD62L+ cells within the T cell population identified by fluorescent emission from APC-
conjugated antibodies for CD62L. 
 




Note:  All cells are included in the initial gate when quantifying CD11b+ cells as 
these cells are not T Lymphocytes but cells of the innate immune system such as 
monocytes, granulocytes, macrophages, and natural killer cells. The cluster of 
debris in the bottom left of the initial FSC Vs. SSC plot is excluded but all cells 






Figure 56: Initial gate for Panel B.  All cells are included in the gate, the cluster of debris in the bottom left is 
excluded.   




CD11b+ cells within the ‘all cells’ gate were selected as shown in Figure 57: 
CD3+CD44+ Cells within the lymphocyte population were selected as shown in 
Figure 58. 
Figure 57: CD11b+ cells identified by fluorescent emission from EF660-conjugated antibodies for CD11b. The Y-axis 
shows APC because the fluorescent emission from EF660 is at the same wavelength as APC and the same detector 
is used.  
 
Figure 58: Antigen-experienced cells within the lymphocyte population identified by the fluorescent 
emission from anti-CD44 antibodies conjugated to AF488.  




 Panel C Specific: 
Figure 59: Helper T cells within the lymphocyte population identified by the fluorescent emission from anti-
CD4 antibodies conjugated to AF488.  
 
Figure 60: Cytotoxic T cells within the lymphocyte population identified by the fluorescent emission from 
anti-CD8 antibodies conjugated to PerCP/Cy5.5. 
 






No significant difference in the expression of CD4, CD8, CD62L, CD44 or 
CD11b was observed as a result of either positive allosteric modulation of 
mGluR5 using LSN2814617 or of antagonism of the receptor using MPEP or 












The % of T cells expressing each of the antigens measured from each animal were averaged 
for each stage of the study (baseline, vehicle, drug treatment, washout).  The same was done 
for the total % all of cells expressing CD11b. 
 






Figure 61:  Expression of CD markers of interest on CD3+ T cells isolated from rats as determined by FACS.  Blood was taken 
from Wistars for the LSN2814617 study (A and B) and SHRs for MPEP (C-E) and MTEP (F).  Blood was drawn after a one 
week period of baseline, vehicle, drug and washout.  No significant differences were observed.  P-Values determined by T-test. 
Error bars show SEM.  
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No Significant Differences in Immunophenotype Were Observed in 
Response to Modulation of mGluR5: 
No significant difference in the expression of CD4, CD8, CD62L, CD44 or 
CD11b was observed as a result of either positive allosteric modulation of 
mGluR5 using LSN2814617 (Figure 61 A and B) or of antagonism of the 
receptor using MPEP (Figure 61 C-E) or MTEP (Figure 61 F).  This may be due 
to the fact that blood was drawn via tail vein bleed at the end of each one-week 
phase (baseline, vehicle, drug and washout).  The results from Chapter 3 show 
that changes in blood pressure resulting from modulation of mGluR5 
disappeared after 2-3 days so it is possible that any changes in 
immunophenotype that did occur were missed by the time blood was collected.  
It is of course possible that no changes occurred – the results from my study do 
not allow any decisive conclusion to be made. 
The rationale for this study was that the sympathetic nervous system is pro-
inflammatory as discussed in Chapter 1.   We published a paper recently (Marvar 
et al., 2016) demonstrating that inhibition of leukotriene B4 receptor reduces 
blood pressure and improves autonomic function (baroreflex) in SHR – The 
immune system is most certainly involved in hypertension in rats as well as 
humans. 
No Significant Differences in Immunophenotype Were Observed between 
SHR and Normotensive Wistar Controls. 
The rats receiving LSN2814617 (Figure 61 A and B) were normotensive Wistars 
and those receiving the antagonists were hypertensive SHRs (Figure 61 C-F).  
No significant difference in the expression of CD4, CD8, CD62L, CD44 or 




CD11b was observed between Wistars and SHRs.  This was not expected since 
the results from Chapter 4, as well as those from a paper we published recently 
(Marvar et al., 2014) show that hypertensive human males exhibit a pro-
inflammatory phenotype constituting an increase in the percentage of T-cells that 
are antigen-experienced.  There are a wide array of differences between the 
immune systems of humans and rodents (Mestas & Hughes, 2004).  Potentially 
of significance to this particular study is the fact that human T cells express 
MHCII whereas those of rodents do not.  MHCII allows human T cells to take 
up, process and present antigen and the fact that they also express B7 co-
stimulatory protein means they are able to amplify inflammatory responses by 
activating other cells of the adaptive immune system (Barnaba et al., 1994; 
Denton et al., 1999), a role reserved for specialist antigen presenting cells in 
rodents.  It is possible that this attenuates the hypertensive effect of ‘neoantigens’ 
formed by oxidative modification of endogenous proteins because the antigenic 
signal is not amplified in the same way as it is in humans. 
Hypertension has a variety of causes and these may be different depending on 
the individual.  Perhaps in the case of humans, inflammation is a major driving 
factor in many and in others it is not, leaving an inflammatory component in the 
average human.  SHRs are inbred so they are more likely to share particularities 
of mechanistic causes of hypertension.  
Lifestyle factors such as diet and behaviour (exercise etc.) are known to be 
contributing factors to hypertension as discussed in chapter 1.  It is possible that 
pro-inflammatory factors such as poor diet and sedentary lifestyle in humans 
begin the inflammatory cycle we see in hypertension.  These factors do not come 




into play with experimental rats, which eat a healthy diet and maintain healthy 
levels of physical activity under laboratory conditions. 
Limitations and Further work: 
When this study began, I did not know what effect the PAM or the antagonists 
would have on blood pressure over the course of the week-long treatment phase 
and I did not anticipate the tolerance that I observed.  If I was to study this 
further, I would take blood samples from the animals at the peak of the observed 
effects on blood pressure in order to determine whether T cells exhibit a more 

















Chapter 6:  Conclusions 
In Chapter 2, I demonstrated that mGluR5 is expressed in a variety of key nuclei 
of the medulla, midbrain and hypothalamus that are known to be involved in 
autonomic regulation of blood pressure.  My findings build upon the work of Li 
and Pan, who previously inferred the presence of mGluR5 in the PVN by 
microinjecting compounds that modulate mGluR5 and eliciting measurable 
pressor and depressor responses.  Li and Pan also quantified mGluR5 isolated 
from tissue homogenates of the PVN using Western Blotting and qPCR, 
providing further evidence of mGluR5 expression in this nucleus (Li and Pan, 
2010). 
Prior to my study there was limited evidence of mGluR5 expression in the PAG.  
Palazzo et al. inferred the presence of mGluR5 in the PAG when they found that 
MPEP abrogated responses they had elicited via cannabinoid receptor 
stimulation (Palazzo et al., 2012).   One group had previously localised mGluR5 
in the NTS (Hay et al., 1999) and another provided evidence for the expression 
of Group 1 mGluRs in the NTS and CVLM, although their methods were not 
selective for either mGluR1 or mGluR5 and so this study does not provide 
evidence of mGluR5 expression in these nuclei specifically (Austgen et al., 
2009).  To my knowledge, no group has published convincing evidence of 
mGluR5 expression in the A5 area or the CVLM.   
My immunohistochemistry study provides corroborating evidence of mGluR5 
expression in the PVN, NTS and PAG, using a different methodology to those 
used by previous groups.  The staining observed in the A5 area of the 
ventrolateral pons potentially points to a novel finding of mGluR5 expression in 




this area but due to the limitations discussed in Chapter 2 it is not possible for me 
to conclude that the A5 adrenergic neurons in particular express mGluR5. 
In Chapter 3, I demonstrated that positive allosteric modulation of mGluR5 via 
LSN2814617 causes an increase in blood pressure and that blood pressure can be 
reduced with MTEP, a selective antagonist for the receptor.  These findings were 
not surprising given the fact that mGluR5 activation is known to increase 
neuronal excitability and that the receptor is expressed in nuclei involved in 
blood pressure control and where excitatory signalling is glutamatergic as 
discussed in Chapter 1.  
The observation that the effects of mGluR5 modulation were tolerated relatively 
quickly (in that both BP and HR trended back to baseline despite continued drug 
administration) was surprising.  The mechanism by which this tolerance occurred 
cannot be determined from my study but I discussed some of the possibilities in 
Chapter 3.  This tolerance of the pharmacological effects of the compounds, 
combined with the fact that systemic modulation of glutamatergic signalling 
would likely cause a variety of off-target effects, reduces the possibility that 
MTEP will ever be used as a novel therapeutic agent to control hypertension in 
humans.  Regardless, the effects I observed provide a practical demonstration 
that mGluR5 plays a role in signalling that is integral to the control of blood 
pressure.  As I discussed in Chapter 3, my study does not determine the degree to 
which mGluR5 modulation affects sympathetic outflow specifically and 
additional studies would be required to determine this. 
In Chapter 4, I clearly demonstrated a relationship between the adaptive immune 
system and hypertension.  My investigation of the balance between the CD45RO 
and CD45RA isotypes of CD45 expressed by T cells, along with expression of 




CD62L, CD196 and CD197 builds upon the novel findings we published 
previously (Marvar et al., 2014).  The expansion of this work provides further 
valuable insight into how the adaptive immune system promotes hypertension.  
My finding that the percentage of T-cells that are antigen experienced is 
significantly increased in hypertensive human males is in agreement with the 
hypothesis that hypertension causes the production of reactive oxygen species 
which modify endogenous proteins such that they are no longer recognised as 
self, promoting an auto-immune inflammatory response which itself is pro-
hypertensive (Figure 7). My findings do not, however, directly support this 
hypothesis since I do not have any evidence for the existence of ‘neoantigens’, I 
show only that T cells are activated in hypertension. My findings fit with data 
from other groups implicating T cells in hypertension as discussed in Chapter 1, 
thereby contributing to the growing body of evidence linking the adaptive 
immune system with hypertension. 
Chapter 5 did not provide such valuable insight.  All that can be determined from 
this study is that male SHRs do not exhibit a pro-inflammatory 
immunophenotype as hypertensive human males do and that pharmacological 
modulation of mGluR5 does not cause long-term changes in T-cell 
immunophenotype.  Whether or not mGluR5 modulation causes short-term 
changes in immunophenotype that coincide with the pressor and depressor 
effects I observed is a question that I failed to answer due to the possibility that 
my blood-sampling time point may have missed this effect. 
Overall my project has demonstrated that mGluR5 plays a role in modulating the 
control of blood pressure and that the adaptive immune system is involved in 
either the generation or maintenance of hypertension. 






















































































CD45RO Vs. CD45RA and CD196 Expression in Pre 
Vs. Post-Menopausal women.
Pre PostFigure 62:  T cell phenotype in post-menopausal hypertensive human females vs. aged-matched 
normotensive controls.  A:  CD4+ vs. CD8a+ T cells and CD62L expression on each of the two 
subpopulations. B: CD197 expression on all T cells, helper T cells and cytotoxic T cells 

































CD4 Vs. CD8 and CD62L Expression in Hypertensive 






















































CD45RO Vs. RA and CD196 Expression in Hypertensive 






Figure 63:  T cell phenotype in untreated hypertensive human males vs. aged-matched normotensive 
controls.  A:  CD4+ vs. CD8a+ T cells and CD62L expression on each of the two subpopulations. B: 
CD197 expression on all T cells, helper T cells and cytotoxic T cells respectively.  C: CD45RO vs. 










Formulations for Solutions Used in Chapter 2: 
Iron Alum: Dissolve 140g of ferric-ammonium sulfate crystals in 400ml of hot 
water. Leave to cool then filter and make up to a volume of 500ml with dilute (6 
N) nitric acid. 
Solochrome Solution: Add 0.5ml conc. sulphuric acid to 0.2g solochrome 
cyanine RS (Eriochrome cyanine R). Stir until dissolved. Add 96ml of distilled 
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